<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id><journal-id journal-id-type="publisher-id">cancers</journal-id><journal-title-group><journal-title>Cancers</journal-title></journal-title-group><issn pub-type="epub">2072-6694</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6826850</article-id><article-id pub-id-type="doi">10.3390/cancers11101574</article-id><article-id pub-id-type="publisher-id">cancers-11-01574</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Many Facets of Tumor Heterogeneity: Is Metabolism Lagging Behind?</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2849-5805</contrib-id><name><surname>Loponte</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="af1-cancers-11-01574">1</xref><xref ref-type="author-notes" rid="fn1-cancers-11-01574">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7776-2896</contrib-id><name><surname>Lovisa</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="af2-cancers-11-01574">2</xref><xref ref-type="author-notes" rid="fn1-cancers-11-01574">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Deem</surname><given-names>Angela K.</given-names></name><xref ref-type="aff" rid="af1-cancers-11-01574">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5182-3320</contrib-id><name><surname>Carugo</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="af3-cancers-11-01574">3</xref><xref rid="c1-cancers-11-01574" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Viale</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="af1-cancers-11-01574">1</xref><xref rid="c1-cancers-11-01574" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-cancers-11-01574"><label>1</label>Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; <email>SLoponte@mdanderson.org</email> (S.L.); <email>AKDeem@mdanderson.org</email> (A.K.D.)</aff><aff id="af2-cancers-11-01574"><label>2</label>Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; <email>SLovisa@mdanderson.org</email></aff><aff id="af3-cancers-11-01574"><label>3</label>TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA</aff><author-notes><corresp id="c1-cancers-11-01574"><label>*</label>Correspondence: <email>ACarugo@mdanderson.org</email> (A.C.); <email>aviale@mdanderson.org</email> (A.V.)</corresp><fn id="fn1-cancers-11-01574"><label>&#x02020;</label><p>These authors contributed equally to the work.</p></fn></author-notes><pub-date pub-type="epub"><day>16</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2019</year></pub-date><volume>11</volume><issue>10</issue><elocation-id>1574</elocation-id><history><date date-type="received"><day>30</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>09</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Tumor functional heterogeneity has been recognized for decades, and technological advancements are fueling renewed interest in uncovering the cell-intrinsic and extrinsic factors that influence tumor development and therapeutic response. Intratumoral heterogeneity is now arguably one of the most-studied topics in tumor biology, leading to the discovery of new paradigms and reinterpretation of old ones, as we aim to understand the profound implications that genomic, epigenomic, and functional heterogeneity hold with regard to clinical outcomes. In spite of our improved understanding of the biological complexity of cancer, characterization of tumor metabolic heterogeneity has lagged behind, lost in a century-old controversy debating whether glycolysis or mitochondrial respiration is more influential. But is tumor metabolism really so simple? Here, we review historical and current views of intratumoral heterogeneity, with an emphasis on summarizing the emerging data that begin to illuminate just how vast the spectrum of metabolic strategies a tumor can employ may be, and what this means for how we might interpret other tumor characteristics, such as mutational landscape, contribution of microenvironmental influences, and treatment resistance.</p></abstract><kwd-group><kwd>intratumor heterogeneity</kwd><kwd>evolution</kwd><kwd>ecosystem</kwd><kwd>adaptation</kwd><kwd>complexity</kwd><kwd>genomics</kwd><kwd>epigenomics</kwd><kwd>reprogramming</kwd><kwd>metabolism</kwd><kwd>response to therapy</kwd><kwd>treatment resistance</kwd></kwd-group></article-meta></front><body><sec id="sec1-cancers-11-01574"><title>1. The Discovery of Tumor Heterogeneity</title><p>Although optical microscopy dates back to the 17th century, it was not until 1833 that a young professor at Humboldt University of Berlin, Johannes Muller, would use this technology to differentiate tumors based on their architecture. Although better known for his contributions to anatomy and physiology, Muller was the first to describe, depict, and catalog epithelial and mesenchymal human tumors based on histological appearance [<xref rid="B1-cancers-11-01574" ref-type="bibr">1</xref>,<xref rid="B2-cancers-11-01574" ref-type="bibr">2</xref>,<xref rid="B3-cancers-11-01574" ref-type="bibr">3</xref>]. Almost two centuries after publication, we can now appreciate that the tables and sketches Muller included in <italic>&#x0201c;Cancer, and of Those Morbid Growths Which May Be Confounded with It&#x0201d;</italic> already captured the heterogeneous essence of human tumors entirely (<xref ref-type="fig" rid="cancers-11-01574-f001">Figure 1</xref>). Muller&#x02019;s pioneering work was further developed by his assistant, Rudolph Virchow, who published his landmark book, <italic>Cellular Pathology</italic>, 25 years later [<xref rid="B4-cancers-11-01574" ref-type="bibr">4</xref>]. Virchow went on to be the first to document and describe an astonishing number of diseases and biological structures and processes, earning him the moniker, &#x0201c;<italic>the Father of Modern Pathology</italic>&#x0201d; or, to his peers, the &#x0201c;<italic>Pope of Medicine</italic>&#x0201d; [<xref rid="B5-cancers-11-01574" ref-type="bibr">5</xref>]. Regarding tumors, Virchow&#x02019;s detailed descriptions of pleomorphism among cancer cells and the tumor microenvironment confirm, like his mentor, that intra-tumor heterogeneity is a long-established clinical observation.</p><p>It soon became clear that cancer cells were heterogenous at the functional level as well. Although it had been known that only viable cells could propagate tumors from mouse to mouse in transplantation, it was not until the 1930s that it was demonstrated that not all viable tumor cells were endowed with the same tumorigenic capacity [<xref rid="B6-cancers-11-01574" ref-type="bibr">6</xref>]. This was evaluated in humans in an ethically questionable study (which admits &#x0201c;most patients were interviewed before the procedure and informed of the experimental nature and general purpose of the study&#x0201d;) in which Southman and Brunschwig directly tested the autotransplantability of human cancer cells by subcutaneously injecting cell suspensions or tissue fragments derived from the patients&#x02019; own laparotomy or biopsy tissue to study the frequency of tumor development. Transplanted cells grew in less than 20% of patients studied, confirming the authors&#x02019; belief that not all cancer cells are equally capable of sustaining tumor growth [<xref rid="B7-cancers-11-01574" ref-type="bibr">7</xref>]. These studies eventually led to the development of quantitative assays to investigate tumorigenic potential and, consequently, to the identification of cancer stem cells [<xref rid="B8-cancers-11-01574" ref-type="bibr">8</xref>].</p><p>The realization that tumor cells are not all the same became even more compelling upon the demonstration in the late 1950&#x02013;60s that tumors are monoclonal in origin. First, cytogenetic studies, then the assessment of allelic metabolic isoenzymes, immunoglobulin rearrangements, and genomic DNA polymorphisms, all consistently led to the same conclusion that human tumors derive from one single transformed cell [<xref rid="B9-cancers-11-01574" ref-type="bibr">9</xref>]. To explain intrinsic variability among a clonal population of cells, it was hypothesized that tumors evolve and become progressively heterogenous over time. In 1976, only a few years after the identification of the Philadelphia chromosome, which was the first chromosomal rearrangement linked to the pathogenesis of a human neoplasia, Peter Nowell published his seminal work, &#x0201c;<italic>The Clonal Evolution of Tumor Cell Populations&#x0201d;</italic> [<xref rid="B10-cancers-11-01574" ref-type="bibr">10</xref>]. Known as the &#x0201c;<italic>Father of Tumor Evolution</italic>&#x0201d;, Nowell conceptualized the first model of evolution, which is still considered valid. Based on published reports, he conceived tumorigenesis as a stepwise evolutionary process in which tumor cells acquire genomic alterations from time to time, that eventually generate new variants of altered cells. He writes, "<italic>Nearly all of these variants are eliminated, because of metabolic disadvantage or immunologic destruction, but occasionally one has an additional selective advantage with respect to the original cells becoming the precursor of a new predominant subpopulation. Over time, there is sequential selection of sublines which are increasingly abnormal, both genetically and biologically.</italic>" Of note, Nowell considered genomic instability to be the driving force of tumor evolution and was the first to recognize the environment and external perturbations, such as therapeutics, as important factors in shaping tumor heterogeneity [<xref rid="B10-cancers-11-01574" ref-type="bibr">10</xref>].</p><p>A couple of years later, another fundamental manuscript was published by a group of scientists led by Gloria Heppner in which, through the characterization of distinct clonal lineages isolated from the same neoplasm, the authors formally demonstrated that cells with different genomic traits coexist within the same tumor and, more importantly, behave differently from each other [<xref rid="B11-cancers-11-01574" ref-type="bibr">11</xref>]. This study represented an inflection point in cancer biology research and prompted the field to explore experimental methods to model intratumor heterogeneity and its influence on treatment response and drug resistance, invasion and metastasis, cross-talk among cells and between tumor cells, and the microenvironment [<xref rid="B12-cancers-11-01574" ref-type="bibr">12</xref>,<xref rid="B13-cancers-11-01574" ref-type="bibr">13</xref>,<xref rid="B14-cancers-11-01574" ref-type="bibr">14</xref>,<xref rid="B15-cancers-11-01574" ref-type="bibr">15</xref>,<xref rid="B16-cancers-11-01574" ref-type="bibr">16</xref>,<xref rid="B17-cancers-11-01574" ref-type="bibr">17</xref>,<xref rid="B18-cancers-11-01574" ref-type="bibr">18</xref>]. Heppner was the first to introduce and experimentally test numerous concepts that are now tenets in cancer biology, including describing tumor spatial heterogeneity and postulating the existence of multiple mechanisms driving tumor evolution, including epigenetic alterations and changing microenvironmental stressors. However, Heppner&#x02019;s name is likely best known for her population biology approach to the study of human tumors. She envisioned neoplasia as &#x0201c;<italic>societies highly adapted for survival</italic>&#x0201d;, where interactions between cells are critically important, and the equilibrium among different subpopulations of cells continuously change over time. In her words, &#x0201c;<italic>the properties of the tumor cannot be deduced by the simple addition of its component parts &#x02026; tumor societies survive natural and artificial (therapeutic) selection through heterogeneity by producing new variants to &#x02018;outflank&#x02019; it&#x0201d;</italic> [<xref rid="B19-cancers-11-01574" ref-type="bibr">19</xref>]. Thus, Heppner was the first to recognize that interactions among clonal lineages influence the biological behaviors of tumors, including treatment response. Her vision and exceptional contributions to the field have been summarized in an essay published in 1984 [<xref rid="B19-cancers-11-01574" ref-type="bibr">19</xref>], deservedly recognized as one of the most influential manuscripts ever published in <italic>Cancer Research</italic> [<xref rid="B20-cancers-11-01574" ref-type="bibr">20</xref>].</p></sec><sec id="sec2-cancers-11-01574"><title>2. Current Models of Tumor Evolution</title><p>Heppner&#x02019;s definition of tumors as a &#x0201c;<italic>Complex Ecosystem</italic>&#x0201d; has increased in popularity due to new sophisticated technologies that have made it possible to validate many of her hypotheses. Over the last two decades, the advent and plummeting cost of next-generation sequencing (NGS), as well as the launch of cancer genomics programs led by non-profit and public consortia, have generated large-scale genomic datasets for tens of thousands of human tumors.</p><p>The first direct consequence of the genomic revolution is the revelation that long-standing models used to explain tumor progression and evolution were too simplistic. The step-wise &#x0201c;linear model&#x0201d; of tumor progression, first conceptualized by Foulds and Nowell [<xref rid="B10-cancers-11-01574" ref-type="bibr">10</xref>,<xref rid="B21-cancers-11-01574" ref-type="bibr">21</xref>] as a legacy of the old studies on chemical carcinogenesis and then expanded at the molecular level by Fearon and Vogelstein [<xref rid="B22-cancers-11-01574" ref-type="bibr">22</xref>], indeed has a very limited application [<xref rid="B23-cancers-11-01574" ref-type="bibr">23</xref>]. More current models address the accumulation and varied fitness of clonal lineages but differ in their description of how clonal variation emerges. In the <italic>branching model</italic>, tumor cells evolve and drift from a founder clone characterized by &#x0201c;trunk mutations&#x0201d; into branches with accumulating genetic diversity (&#x0201c;subclonal mutations&#x0201d;) [<xref rid="B24-cancers-11-01574" ref-type="bibr">24</xref>]. This model, supported by multiple studies in numerous cancers, accounts for a continuous increase in tumor complexity wherein tumor lineages expand based on the fitness conferred by the constellation of newly acquired genomic abnormalities. An alternative model is the &#x0201c;<italic>punctuate&#x0201d;,</italic> or <italic>&#x0201c;big bang model&#x0201d;</italic>, which describes the acquisition of genomic aberrations as sudden, discrete mutational bursts or cataclysmic chromosomal events [<xref rid="B23-cancers-11-01574" ref-type="bibr">23</xref>,<xref rid="B25-cancers-11-01574" ref-type="bibr">25</xref>,<xref rid="B26-cancers-11-01574" ref-type="bibr">26</xref>], such as chromothripsis [<xref rid="B27-cancers-11-01574" ref-type="bibr">27</xref>]. These massive genomic events would occur early during tumorigenesis to create, at the onset of disease, the entire pool of clonal diversity that usually is found in late-stage tumors (<xref ref-type="fig" rid="cancers-11-01574-f002">Figure 2</xref>) [<xref rid="B28-cancers-11-01574" ref-type="bibr">28</xref>,<xref rid="B29-cancers-11-01574" ref-type="bibr">29</xref>].</p><p>Thus, as postulated by Heppner, it is now recognized that, despite a monoclonal origin, tumors at diagnosis are the variegated result of a complex process that yields many genomically, epigenetically, metabolically, and spatially different subclones that comprise a complex ecosystem (<xref ref-type="fig" rid="cancers-11-01574-f003">Figure 3</xref>). In fact, the progression of a tumor is shaped by its own heterogeneity, and different stages of tumor development maintain a structured cellular hierarchy that is phenotypically and spatially well-defined, and wherein less-aggressive clones spatially suppress their more aggressive counterparts [<xref rid="B30-cancers-11-01574" ref-type="bibr">30</xref>]. Somewhat paradoxically, in the clinic, we must contend with the fact that anti-cancer drugs disrupt this equilibrium [<xref rid="B31-cancers-11-01574" ref-type="bibr">31</xref>] and can even select for more aggressive clones in advanced, and more anaplastic stages of tumor evolution [<xref rid="B32-cancers-11-01574" ref-type="bibr">32</xref>,<xref rid="B33-cancers-11-01574" ref-type="bibr">33</xref>].</p></sec><sec id="sec3-cancers-11-01574"><title>3. From Genomics to Metabolomics: The Role of Genes in Reprogramming Tumor Metabolism</title><p>It is well established that the genomic events responsible for transformation and tumor progression, such as activation of oncogenic signaling and loss of function of tumor suppressors, are also driving forces for the metabolic rewiring of tumors. Deregulation of glucose metabolism, first described by Otto Warburg in the 1920s and termed the <italic>Warburg effect</italic> in his honor, dominated the field of cancer metabolism for decades [<xref rid="B34-cancers-11-01574" ref-type="bibr">34</xref>,<xref rid="B35-cancers-11-01574" ref-type="bibr">35</xref>]. The &#x0201c;<italic>aerobic fermentation</italic>&#x0201d; described by Warburg (also known as aerobic glycolysis) [<xref rid="B36-cancers-11-01574" ref-type="bibr">36</xref>], was based on the observation that tumors, unlike normal resting tissues, are able to produce lactate even in the presence of oxygen. Warburg attributed this event to the dysfunction of mitochondria in tumor cells that forced reliance on glycolysis for their energetics. However, although rapidly proliferating tumor cells are highly glycolytic and can use lactate production to regenerate NAD+, it is now understood that the upregulation of glucose and glutamine consumption by dividing cells is to accommodate the molecular building blocks needed for biosynthetic purposes as opposed to increased energy requirements [<xref rid="B37-cancers-11-01574" ref-type="bibr">37</xref>]. Moreover, the idea that mitochondrial defects are the primary driver of glycolytic flux has been discarded due to the demonstration that aberrant activation of prototypical oncogenes, such as <italic>MYC</italic>, <italic>KRAS</italic>, <italic>EGFR</italic>, <italic>PI3K</italic>, <italic>AKT</italic>, profoundly affects cell metabolism and increases the uptake and utilization of glucose and glutamine (<xref ref-type="fig" rid="cancers-11-01574-f004">Figure 4</xref>) [<xref rid="B38-cancers-11-01574" ref-type="bibr">38</xref>,<xref rid="B39-cancers-11-01574" ref-type="bibr">39</xref>,<xref rid="B40-cancers-11-01574" ref-type="bibr">40</xref>,<xref rid="B41-cancers-11-01574" ref-type="bibr">41</xref>,<xref rid="B42-cancers-11-01574" ref-type="bibr">42</xref>,<xref rid="B43-cancers-11-01574" ref-type="bibr">43</xref>].</p><p>Another key mediator of glycolytic metabolism in tumors is HIF1&#x003b1;, which belongs to the family of hypoxia-inducible transcription factors. HIF1&#x003b1; is a central player in oxygen sensing and homeostasis [<xref rid="B44-cancers-11-01574" ref-type="bibr">44</xref>]. The transcriptional activity of HIF complexes is suppressed during normoxia; however, when molecular oxygen is insufficient to support normal dioxygenase activity (e.g., hypoxia), HIF1&#x003b1; is not hydroxylated at prolyl and asparaginyl residues. As a consequence, in the absence of hydroxylation, HIF1&#x003b1; is not recognized as a substrate for proteasomal degradation by the ubiquitin ligase pVHL&#x02013;elonginB&#x02013;elonginC complex, and the increased level of HIF induces complex transcriptional programs that sustain angiogenesis, cell migration, and proliferation, as well as glycolytic activation [<xref rid="B44-cancers-11-01574" ref-type="bibr">44</xref>]. Because of the hypoxic microenvironment caused by fast-expanding masses, HIF activation is a common feature of many human cancers. In addition to hypoxia, HIF stabilization and activation of downstream transcriptional programs can result from loss of function mutations of <italic>VHL</italic>, as well as mutant alleles of metabolic enzymes, such as <italic>FH-</italic> or <italic>SDH-</italic> mutant tumors, in which high levels of the TCA intermediates fumarate or succinate, respectively, interfere with dioxygenase activity and increase HIF1&#x003b1; stability [<xref rid="B43-cancers-11-01574" ref-type="bibr">43</xref>,<xref rid="B44-cancers-11-01574" ref-type="bibr">44</xref>]. These facts suggest that multiple oncogenes and transformational events all lead to the same phenotypic outcome: activation of a common set of metabolic programs that increase glycolytic flux. But, should we expect this to be the case?</p><p>To address this important issue, we must first consider that what has been described as tumor metabolic reprogramming or rewiring is, in reality, not a feature specific to tumor cells. In fact, tumor metabolism, including the Warburg effect, recapitulates the metabolism of actively dividing normal cells [<xref rid="B45-cancers-11-01574" ref-type="bibr">45</xref>]. To undergo a division and generate two daughter cells, both normal and cancer cells rely on activation of the same biosynthetic programs to expand biomass, and because the major carbon sources that fuel the increased anabolic processes are glucose and glutamine, all dividing cells rely on glycolysis and glutaminolysis [<xref rid="B38-cancers-11-01574" ref-type="bibr">38</xref>,<xref rid="B39-cancers-11-01574" ref-type="bibr">39</xref>,<xref rid="B40-cancers-11-01574" ref-type="bibr">40</xref>,<xref rid="B41-cancers-11-01574" ref-type="bibr">41</xref>,<xref rid="B42-cancers-11-01574" ref-type="bibr">42</xref>,<xref rid="B43-cancers-11-01574" ref-type="bibr">43</xref>]. Glycolysis, the breakdown of one six-carbon molecule of glucose into two three-carbon pyruvate molecules, is probably the most important metabolic pathway for dividing cells. The intermediate molecules of glycolysis fuel multiple collateral anabolic pathways, making glycolysis the hallmark of active proliferation. Glycolic metabolites fuel the generation of nucleotides (ribose), triglycerides, phospholipids (glycerol), and important amino acids such as alanine, serine, and glycine, and they provide reducing equivalents for anabolic reactions (NADPH). Pyruvate, the final product of glycolysis, if not converted into lactic acid by lactate dehydrogenase (LDH), enters the citric acid cycle (TCA) as acetyl-CoA or oxaloacetate, where pyruvate-derived carbo-skeletons can be used as intermediates for other biosynthetic processes, such as synthesis of fatty acids or cholesterol. Like glucose, glutamine is an important source of carbon and nitrogen for dividing cells [<xref rid="B40-cancers-11-01574" ref-type="bibr">40</xref>,<xref rid="B46-cancers-11-01574" ref-type="bibr">46</xref>]. Upon uptake, glutamine is converted to glutamate by glutaminase (GLS), and subsequently to &#x003b1;-ketoglutarate after modification by transaminases (GOT) or glutamate dehydrogenase (GLDH). &#x003b1;-ketoglutarate enters the TCA cycle and, through further modifications to oxaloacetate, sustains the generation of aspartate, an essential substrate for nucleotide synthesis. Glutamine and glutamate also serve as key nitrogen donors for many transamination reactions important for the production of other non-essential amino acids [<xref rid="B46-cancers-11-01574" ref-type="bibr">46</xref>]. In light of this heavy reliance on glucose and glutamine to supply molecular intermediates toward the synthesis of all four major types of biomolecules, it becomes clear why cells increase glucose and glutamine uptake to divide.</p><p>The coordination of the cell cycle with changes in anabolic metabolism during cell division is largely through the <italic>MYC</italic> family of transcription factors (hereafter <italic>MYC</italic> refers to <italic>cMYC</italic>). Thought to be a general transcriptional amplifier that targets all active promoters and enhancers in the genome [<xref rid="B47-cancers-11-01574" ref-type="bibr">47</xref>], it has recently been demonstrated that <italic>MYC</italic> regulates a discrete set of genes [<xref rid="B48-cancers-11-01574" ref-type="bibr">48</xref>]. A critical node downstream of distinct signaling pathways that lead to cell growth and division, MYC executes its proliferation program also through the activation of metabolic functions that fulfill the anabolic requirements of a dividing cell, including genes that control nucleotide and RNA metabolism, ribosome biogenesis, protein synthesis, and energetic (glucose) metabolism [<xref rid="B39-cancers-11-01574" ref-type="bibr">39</xref>,<xref rid="B48-cancers-11-01574" ref-type="bibr">48</xref>]. Beyond MYC, a direct link between the Warburg effect and the cell cycle machinery has also been documented, which lends additional support to an intrinsic coupling between the cell cycle and anabolic metabolism [<xref rid="B49-cancers-11-01574" ref-type="bibr">49</xref>]. It has been demonstrated that, in normal dividing cells, such as embryonic cells or T-lymphocytes, the anaphase-promoting complex/cyclosome-Cdh1 (APC/C-Cdh1), a key regulator of the G1-S transition, inhibits glycolysis and glutaminolysis. Through its E3 ligase activity, the APC/C-Cdh1 complex targets 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 and glutaminase-1 for degradation. Because the APC/C-Cdh1 complex is tightly regulated during the cell cycle, its inactivation at the initiation of S-phase would enhance glycolytic flux and glutaminolysis. Reactivation of the complex in late mitosis, when the biosynthetic needs of cells decrease, would reverse this effect [<xref rid="B50-cancers-11-01574" ref-type="bibr">50</xref>,<xref rid="B51-cancers-11-01574" ref-type="bibr">51</xref>]. As motifs recognized by Cdh1 have been identified in many other metabolic enzymes, including pyruvate carboxylase, malate dehydrogenase-1, and acetyl-CoA carboxylase-1, one can speculate that the coupling between cell cycle machinery and metabolism may exert a broader role in the regulation of anabolic processes during specific phases of cell division [<xref rid="B51-cancers-11-01574" ref-type="bibr">51</xref>].</p><p>Not surprisingly, tumor suppressors exert exactly opposite effects of MYC on cell metabolism, suggesting a &#x0201c;gatekeeper&#x0201d; role for metabolism programs to restrain proliferation and perhaps transformation. TP53, through transcriptional regulation of target genes such as TP53-induced glycolysis and apoptosis regulator (<italic>TIGAR</italic>) and <italic>Parkin</italic>, down-regulates the glycolytic pathway [<xref rid="B52-cancers-11-01574" ref-type="bibr">52</xref>,<xref rid="B53-cancers-11-01574" ref-type="bibr">53</xref>]. TIGAR, a fructose bisphosphatase, drastically reduces glycolytic flux by degrading fructose-2,6-bisphosphate, a potent positive allosteric effector of 6-phosphofructo-1-kinase (PFK1) [<xref rid="B52-cancers-11-01574" ref-type="bibr">52</xref>]. p53 also suppresses glycolysis through the direct transcriptional repression of glucose transporters, hexokinases, and phosphoglycerate mutase enzymes [<xref rid="B54-cancers-11-01574" ref-type="bibr">54</xref>,<xref rid="B55-cancers-11-01574" ref-type="bibr">55</xref>,<xref rid="B56-cancers-11-01574" ref-type="bibr">56</xref>,<xref rid="B57-cancers-11-01574" ref-type="bibr">57</xref>]. The regulation of mitochondrial activity by p53 has also been described. Through the downregulation of the lactate/proton symporter, monocarboxylate transporter 1 (<italic>MCT1</italic>), as well as downregulating enzymes that inhibit pyruvate dehydrogenase (PDH) activity, p53 activity directly limits lactate production and favors the conversion of pyruvate into acetyl-CoA to fuel the TCA cycle [<xref rid="B58-cancers-11-01574" ref-type="bibr">58</xref>,<xref rid="B59-cancers-11-01574" ref-type="bibr">59</xref>]. p53 also regulates mitochondria biogenesis [<xref rid="B60-cancers-11-01574" ref-type="bibr">60</xref>,<xref rid="B61-cancers-11-01574" ref-type="bibr">61</xref>] and the expression of proteins involved in the assembly and maintenance of respiratory complexes in the electron transport chain [<xref rid="B62-cancers-11-01574" ref-type="bibr">62</xref>,<xref rid="B63-cancers-11-01574" ref-type="bibr">63</xref>]. All of these metabolic regulations are lost upon mutation or deletion of <italic>TP53</italic> [<xref rid="B64-cancers-11-01574" ref-type="bibr">64</xref>,<xref rid="B65-cancers-11-01574" ref-type="bibr">65</xref>].</p><p>If all proliferative programs lead to anabolic metabolism, it might be expected that, in comparison with other cellular phenotypes, metabolism programs should be relatively homogeneous among tumors. However, we are now keenly aware that this is not the case. Although all oncogenes drive proliferation, distinct oncogenes activating different signaling networks can variably engage metabolic pathways, resulting in differential utilization of metabolites [<xref rid="B46-cancers-11-01574" ref-type="bibr">46</xref>,<xref rid="B66-cancers-11-01574" ref-type="bibr">66</xref>,<xref rid="B67-cancers-11-01574" ref-type="bibr">67</xref>]. Also, tumors arising from different tissues, even if they share the same driver mutations, may present with distinct metabolism due to the differences in the cell of origin [<xref rid="B43-cancers-11-01574" ref-type="bibr">43</xref>,<xref rid="B67-cancers-11-01574" ref-type="bibr">67</xref>]. Further, external perturbations to the tissue of origin or the tumor may influence cell metabolism. Thus, despite their common disposition to proliferate and spread, tumors can dysregulate and hijack metabolic programs in numerous, highly specific ways to survive.</p></sec><sec id="sec4-cancers-11-01574"><title>4. Metabolic Intratumor Heterogeneity</title><p>Because genomic events profoundly affect tumor metabolism, based on the remarkable genomic and functional heterogeneity described within a single cancer, should we expect a corresponding degree of intratumor metabolic heterogeneity? Driver mutations usually represent &#x02018;<italic>trunk</italic>&#x02019; genomic events&#x02014;aberrations acquired early during progression and shared by the vast majority of cells within the tumor&#x02014;which may suggest that little or no functional variability would be expected between tumor cells. However, considering cell proliferation as an excellent example of a tumor cell phenotype, we recognize striking variability among cells that share a similar mutational burden, wherein dividing cells are typically represented by a very small subpopulation. This was first demonstrated in the late 1960s when Bayard Clarkson conducted pulse-chase experiments with 3H-thymidine directly in patients with acute myeloid leukemia (AML) to evaluate tumor proliferation in vivo [<xref rid="B68-cancers-11-01574" ref-type="bibr">68</xref>,<xref rid="B69-cancers-11-01574" ref-type="bibr">69</xref>]. His unbiased approach demonstrated that, even in this extremely aggressive form of cancer, leukemic blasts were almost entirely post-mitotic, with only a minority (5%) of cells actively dividing. His work went on to show that the proliferating cell subpopulation was not homogeneous, but was comprised largely of fast-cycling cells (doubling time of one day), as well as a smaller proportion of slow-growing cells (termed &#x0201c;<italic>dormant</italic>&#x0201d;) that were characterized by infrequent divisions (doubling time lasting from weeks to months). Similarly, using molecular barcoding to track the evolution of primary human tumors in vitro and in vivo, our group recently found that, in pancreatic cancer, ~70% to 80% of cells are post-mitotic and functionally exhausted [<xref rid="B31-cancers-11-01574" ref-type="bibr">31</xref>].</p><p>The clear evidence that tumor cells can behave so differently, even being mutationally similar and possessing a potent oncogene such as mutated KRAS, reminds us again of Heppner&#x02019;s description of tumors as complex ecosystems. We know now that tumors, like normal tissues, are organized in hierarchies consisting of slow-growing stem cells, transiently amplifying progenitors, and a large number of cells that have exited the cell cycle [<xref rid="B70-cancers-11-01574" ref-type="bibr">70</xref>]. Our explosion in understanding epigenetic regulation at the molecular level in developmental and oncogenic programs has synergized to shed new light on the intersection between tumor hierarchy and genetic context. In brief, different epigenetic states or degrees of differentiation characterize the functional compartments of a tumor and, apparently, can override oncogenic signaling. Indeed, the very same oncogene can lead to distinct outputs (cycling vs. non-cycling) when cells transition from one chromatin state to another. Several elegant studies have demonstrated this directly, showing that both tumor cells and nuclei can be successfully reprogrammed to induced-pluripotent or embryonic stem cells irrespectively of their mutational burden. These undifferentiated cells are able to differentiate back to apparently &#x02018;normal&#x02019; cells, and even contribute to the development of adult mice when injected into blastocysts [<xref rid="B71-cancers-11-01574" ref-type="bibr">71</xref>,<xref rid="B72-cancers-11-01574" ref-type="bibr">72</xref>,<xref rid="B73-cancers-11-01574" ref-type="bibr">73</xref>]. Although extreme examples, these data strongly suggest that epigenetic context and chromatin organization can modulate the oncogenic activity of genomic events.</p><p>Similarly, there is direct evidence that epigenetic states can dictate metabolic programs to generate functionally heterogeneous subpopulations of cells that share a nearly identical mutational signature. In pancreatic cancer, our group uncovered the spontaneous emergence of mesenchymal lineages upon the dysregulation of the chromatin remodeling complex SWI/SNF [<xref rid="B74-cancers-11-01574" ref-type="bibr">74</xref>]. Although these mesenchymal cells harbored the same oncogenic <italic>KRAS</italic> mutation as their more epithelial counterparts, these cells were highly aggressive and characterized by low engagement of MAPK signaling and robust activation of MYC that induces protein anabolism, biomass accumulation, and adaptive response to stress [<xref rid="B74-cancers-11-01574" ref-type="bibr">74</xref>]. Since the publication of this manuscript, continued work to characterize the metabolism of clonal lineages has uncovered chromatin modifications that are likely regulating the differential metabolic programs in tumor cells bearing the same genomic aberrations. Another group has recently described a link between SWI/SNF and tumor cell metabolism, reporting a shift toward oxidative metabolism in lung tumor cells with SMARCA4 loss or mutation [<xref rid="B75-cancers-11-01574" ref-type="bibr">75</xref>]. In melanoma, cells with high expression of KDM5B (JARID1A), a histone demethylase, have deregulated bioenergetics and are characterized by a sustained up-regulation of proteins involved in the electron transport chain, the multiprotein enzymatic complexes responsible for mitochondrial respiration, as well as a significant down-regulation of glycolytic enzymes [<xref rid="B76-cancers-11-01574" ref-type="bibr">76</xref>,<xref rid="B77-cancers-11-01574" ref-type="bibr">77</xref>]. Differential expression of KDM5B can thus be used to identify a small subpopulation of melanoma cells characterized by distinct bioenergetics that are resistant to various drugs.</p><p>Today it is well accepted that tumors rely on mitochondrial respiration, and there is a growing list of studies that identify specific cell subpopulations characterized by a more oxidative metabolism with respect to other tumor cells. In particular, slow-growing cells, dormant cells, and cancer stem cells are generally highly reliant on oxidative phosphorylation [<xref rid="B34-cancers-11-01574" ref-type="bibr">34</xref>,<xref rid="B78-cancers-11-01574" ref-type="bibr">78</xref>]. In pancreatic cancer, we identified a subpopulation of cells that were not addicted to the oncogenic signaling and that were dependent on oxidative metabolism for their survival [<xref rid="B79-cancers-11-01574" ref-type="bibr">79</xref>]. Although we first hypothesized that the shift to oxidative metabolism might reflect the low energetic and anabolic rates of these quiescent cells, our recent studies support a much more complicated scenario. Using an innovative platform to generate large cohorts of patient-derived xenotransplants, in which all animals bear tumors with identical clonal composition or <italic>Clonal Replica Tumors (CRTs),</italic> we studied heterogeneous populations of cells and their clonal dynamics in vivo in response to multiple pharmacological perturbations [<xref rid="B31-cancers-11-01574" ref-type="bibr">31</xref>]. Through a systematic and quantitative evaluation of the effects of single- and combined-therapies on tumor clonal composition, we uncovered that relapsed pancreatic tumors previously treated with drugs with unrelated mechanisms of action (gemcitabine, MEK, and PI3K inhibitors) have completely different clonal architecture. This strongly suggests that, inside the same human tumor, different populations of cells characterized by differential sensitivity to drugs preexisted and acquired increased fitness upon therapeutic challenge. Surprisingly, when we isolated and deeply characterized twelve treatment-na&#x000ef;ve clonal lineages based on their in vivo differential sensitivities to drug treatment, we uncovered astonishing heterogeneity with regard to deregulated metabolic pathways. Altered regulation in nearly every metabolic pathway, including oxidative phosphorylation as well as folate, fatty acid, essential amino acids, and sugar anabolism and catabolism, were all observed across the different lineages [<xref rid="B31-cancers-11-01574" ref-type="bibr">31</xref>].</p><p>Although we do not yet know the full extent or significance of this unexpected variability among subclonal lineages that populate the same tumor, these data strongly suggest that metabolic heterogeneity exists and is a pervasive feature of human tumors, at least in pancreatic cancer. Our ability to characterize, capture, and describe the spectrum of metabolic programs present within a tumor has been limited due to the low sensitivity of the technical approaches used to investigate metabolism. Traditional metabolomics and isotope tracing are excellent tools to investigate the average contribution of metabolites to all of the cells under study, but these techniques cannot assess the heterogeneous spectrum of metabolic programs that is being reflected in those averages. Major technological advancements, such as the further development of single-cell metabolomics mimicking the evolution of genomics and transcriptomics, will be required to precisely define the metabolic landscape of tumors. Currently, mass spectrometry imaging (MSI) is the most advanced way to explore metabolic heterogeneity, and both matrix-assisted laser desorption ionization (MALDI) and secondary ion mass spectrometry (SIMS), which already boast sub-micron resolution, will play an important role in the further development of this technology [<xref rid="B80-cancers-11-01574" ref-type="bibr">80</xref>].</p><p>Regional differences in the vasculature, stromal architecture, cell density, and viability contribute to intratumor spatial variegation that can be identified by positron emission tomography (PET), CT, and MRI, especially when used in combination with contrast dyes in order to reveal dynamic changes in blood perfusion. Although these imaging technologies in common use in clinical oncology enable the detection of structural and, to some extent, functional tumor heterogeneity, the data collected is not effectively used in clinical practice [<xref rid="B81-cancers-11-01574" ref-type="bibr">81</xref>]. Because radiologic images represent more than simple pictures [<xref rid="B82-cancers-11-01574" ref-type="bibr">82</xref>], in recent years, the rapid expansion of computational modeling and analysis capabilities has led to the development of &#x02018;radiomics&#x02019;, which are new approaches to extract, quantitatively analyze, and mine all data from digital images deposited in large shared databases, with the goal to improve clinical outcomes for patients with cancer [<xref rid="B82-cancers-11-01574" ref-type="bibr">82</xref>,<xref rid="B83-cancers-11-01574" ref-type="bibr">83</xref>]. This includes also efforts made by multiple investigational groups to develop new, highly sensitive technologies to investigate metabolism in vivo, such as hyperpolarized MRI [<xref rid="B84-cancers-11-01574" ref-type="bibr">84</xref>,<xref rid="B85-cancers-11-01574" ref-type="bibr">85</xref>], or to integrate imaging technologies with genomics and molecular profiling, which have led to substantial advances in our ability to interpret complex radiological images in specific disease contexts [<xref rid="B81-cancers-11-01574" ref-type="bibr">81</xref>,<xref rid="B86-cancers-11-01574" ref-type="bibr">86</xref>,<xref rid="B87-cancers-11-01574" ref-type="bibr">87</xref>,<xref rid="B88-cancers-11-01574" ref-type="bibr">88</xref>]. One notable example of the application of this multipronged approach is the recent work of the research group led by Ralph DeBerardinis. Building on previous studies assessing the feasibility of isotope tracing in vivo [<xref rid="B89-cancers-11-01574" ref-type="bibr">89</xref>,<xref rid="B90-cancers-11-01574" ref-type="bibr">90</xref>,<xref rid="B91-cancers-11-01574" ref-type="bibr">91</xref>], the authors demonstrated the existence of regional metabolic heterogeneity in patients affected by non-small-cell lung cancer [<xref rid="B92-cancers-11-01574" ref-type="bibr">92</xref>]. After the evaluation of glucose uptake, cellularity, and tumor perfusion of pulmonary lesions through <sup>18</sup>fluoro-2-deoxyglucose positron emission tomography (FDG-PET) and multi-parametric MRI, patients received an intraoperative, continuous infusion of unilabelled-<sup>13</sup>C-glucose at the time of surgery. After explant, tumors were subjected to histological and molecular analysis as well as metabolomics and NMR to trace the contribution of glucose-derived carbons to tumor metabolism. This comprehensive approach enabled the authors to determine that glucose utilization, while increased in tumors compared to normal tissue, varies within the same lesion and is affected by regional perfusion. Specifically, low-perfused tumor regions were characterized by a more sustained contribution of glucose to central metabolism versus high-perfused regions, suggesting that tumor cells in less vascularized areas rely more on oxidative metabolism. These observations were consistent with transcriptomic analyses indicating that low-perfused tumors were enriched for gene pathways such as glycolysis, mitochondrial respiration, and the TCA cycle, whereas high-perfused tumors were enriched in the lysosome and amino acid metabolism [<xref rid="B92-cancers-11-01574" ref-type="bibr">92</xref>]. These findings suggest that lung tumors sustain mitochondrial metabolism through a variety of substrates besides glucose, including lactate [<xref rid="B93-cancers-11-01574" ref-type="bibr">93</xref>]. In addition to providing an elegant demonstration of the metabolic heterogeneity of human tumors, these observations demonstrate that the enhanced uptake of <sup>18</sup>FDG-PET in vivo is not an index of tumor glycolytic addiction; rather, it is the consequence of increased glucose oxidative metabolism. These pioneering studies represent a direct challenge to assumptions regarding the Warburg effect in tumor cells that have shaped decades of research into tumor metabolic programming and encourage continued debate regarding current and historical approaches to investigate cellular metabolism in the lab [<xref rid="B94-cancers-11-01574" ref-type="bibr">94</xref>].</p></sec><sec id="sec5-cancers-11-01574"><title>5. Metabolic Heterogeneity in the Tumor Microenvironment</title><p>Tumors are complex tissues comprised of a variety of different cells. As a consequence, besides their intrinsic metabolic requirements, the modulation of cancer cell metabolism can be extrinsically influenced through interactions with the tumor microenvironment. The complex and intricate network formed by cancer cells, matrix-depositing proliferating cancer associated-fibroblasts (CAFs), dysfunctional blood vessels, and immune cells dramatically influence tumor architecture. Inside the tumor, cells must contend with hypoxia, increased interstitial pressure, augmented stiffness, and nutrient deprivation, all of which profoundly shape the metabolic requirements of both stromal and cancer cells [<xref rid="B95-cancers-11-01574" ref-type="bibr">95</xref>]. Amongst cells in the tumor, heterogeneity emerges as cells tune their metabolism programs to compensate for the adverse microenvironment, where nutrient competition leads to the repurposing of nutrients and metabolites, and cells adopt intrinsic metabolic strategies as well as extrinsic nutrient sharing mechanisms to support growth and survival. Below, we review the most recent findings regarding the contribution of two major microenvironmental constituents, CAFs and endothelial cells, to shaping tumor metabolism.</p><sec id="sec5dot1-cancers-11-01574"><title>5.1. Cancer Associated-Fibroblasts (CAFs)</title><p>CAFs participate in the host response to tissue injury caused by cancer cells. They have been shown to critically impact tumorigenesis, and they constitute a synthetic machine that produces many different tumor components [<xref rid="B96-cancers-11-01574" ref-type="bibr">96</xref>]. In addition to paracrine signaling, which is the focus of the following paragraphs, direct cellular contacts between CAFs and cancer cells influence metabolic programs [<xref rid="B97-cancers-11-01574" ref-type="bibr">97</xref>]. Additionally, symbiotic metabolic reprograming between CAFs and cancer cells can also be mediated by the release of small extracellular particles, such as exosomes [<xref rid="B98-cancers-11-01574" ref-type="bibr">98</xref>,<xref rid="B99-cancers-11-01574" ref-type="bibr">99</xref>,<xref rid="B100-cancers-11-01574" ref-type="bibr">100</xref>]. Prostate and pancreas CAF-derived exosomes supply cancer cells with a plethora of metabolites, including amino acids, lipids, and TCA-cycle intermediates [<xref rid="B98-cancers-11-01574" ref-type="bibr">98</xref>,<xref rid="B99-cancers-11-01574" ref-type="bibr">99</xref>]. Conversely, breast cancer-derived exosomes can activate MYC signaling in CAFs through exosome-encapsulated miR105, to induce metabolic reprograming of stromal cells [<xref rid="B100-cancers-11-01574" ref-type="bibr">100</xref>].</p><p>Multiple lines of evidence support that the pro-tumorigenic role of CAFs is exerted by influencing the metabolic microenvironment of tumors. Cancer cells can highjack CAFs to produce energy-rich metabolites to burn via oxidative phosphorylation, in a process termed the <italic>reverse Warburg effect</italic> [<xref rid="B101-cancers-11-01574" ref-type="bibr">101</xref>]. Cancer cells induce oxidative stress in CAFs by producing reactive oxygen species (ROS), which upregulates HIF1&#x003b1; expression in neighboring CAFs due to the inhibition of PHD proteins. In CAFs, increased HIF1&#x003b1; promotes autophagy and degradation of caveolin-1, which negatively regulates nitric oxide (NO) production. The consequent excessive production of NO leads to mitochondria dysfunction, further increases in ROS, mitophagy, and upregulation of glycolysis [<xref rid="B102-cancers-11-01574" ref-type="bibr">102</xref>]. As a consequence, CAFs become highly dependent on aerobic glycolysis and, therefore, produce large quantities of lactate that is then shuttled to cancer cells by the monocarboxylate transporters, MCT4 and MCT1, on CAFs and cancer cells, respectively [<xref rid="B97-cancers-11-01574" ref-type="bibr">97</xref>,<xref rid="B103-cancers-11-01574" ref-type="bibr">103</xref>]. TGF&#x003b2; and PDGF signaling pathways can also induce a HIF1&#x003b1;-mediated metabolic switch towards glycolysis in CAFs. The stabilization of HIF1&#x003b1; under normoxic conditions is reached by a downregulation of the isocitrate dehydrogenase 3 complex (IDH3&#x003b1;). This decreases the intracellular levels of &#x003b1;-ketoglutarate, which, in turn, stabilizes HIF1&#x003b1; by preventing its PHD2-mediated degradation [<xref rid="B104-cancers-11-01574" ref-type="bibr">104</xref>]. Similarly, ketone bodies, such as 3-hydroxy-butyrate, are also generated as end-products of aerobic glycolysis in CAFs and then utilized by cancer cells to fuel oxidative phosphorylation and anabolic metabolism [<xref rid="B105-cancers-11-01574" ref-type="bibr">105</xref>,<xref rid="B106-cancers-11-01574" ref-type="bibr">106</xref>,<xref rid="B107-cancers-11-01574" ref-type="bibr">107</xref>]. This metabolic symbiosis between CAFs and cancer cells, however, does not seem to apply to all CAF-cancer cell interactions. Studies have essentially documented the opposite phenomenon in ovarian and pancreatic cancer, wherein lactate is released in the microenvironment by glycolytic cancer cells and used by CAFs with low glycolytic activity to fuel oxidative phosphorylation [<xref rid="B108-cancers-11-01574" ref-type="bibr">108</xref>,<xref rid="B109-cancers-11-01574" ref-type="bibr">109</xref>].</p><p>Numerous studies also point to an important relationship between CAFs and cancer cells with regard to amino acids. Alanine secreted by autophagic pancreatic stellate cells fuels the TCA cycle of cancer cells and supports biosynthesis of lipids and non-essential amino acids, therefore serving as an alternative carbon source that allows cancer cells to bypass the drastic nutrient depletion in the pancreatic tumor microenvironment [<xref rid="B108-cancers-11-01574" ref-type="bibr">108</xref>]. In ovarian tumors, where glutamine is rare, CAFs upregulate glutamine anabolic pathways to enable glutamine synthesis from atypical sources, such as glutamate and lactate secreted by ovarian cancer cells. Consistent with these observations, co-targeting glutamine synthase and glutaminase impairs ovarian tumor growth and metastasis, representing a promising synthetic lethal approach to target tumor-stroma interdependent metabolism [<xref rid="B109-cancers-11-01574" ref-type="bibr">109</xref>]. Stromal glutamine has also been detected in glioblastoma, where astrocytes can provide glutamine to brain cancer cells [<xref rid="B110-cancers-11-01574" ref-type="bibr">110</xref>], and in pancreas cancer, where adipocytes secrete glutamine that sustains pancreas cancer cell growth [<xref rid="B111-cancers-11-01574" ref-type="bibr">111</xref>]. Stromal release of cysteine has been associated with resistance to chemotherapy in both chronic lymphoid leukemia and ovarian cancer [<xref rid="B112-cancers-11-01574" ref-type="bibr">112</xref>,<xref rid="B113-cancers-11-01574" ref-type="bibr">113</xref>]. Also in ovarian cancer, cytotoxic CD8<sup>+</sup> T cell activity impairs cysteine and glutathione release by CAFs, thereby synthetizing ovarian cancer cells to chemotherapy [<xref rid="B113-cancers-11-01574" ref-type="bibr">113</xref>]. Conversely, the deprivation of amino acids due to competition among cells in the tumor microenvironment can generate an immune-suppressive microenvironment that strongly inhibits the capacity of immune cells to kill cancer cells. Tryptophan catabolism by elevated IDO1 in CAFs generates immunosuppressive kynurenine metabolites, resulting in T cell anergy and apoptosis and negative regulation of dendritic cell immunogenicity [<xref rid="B114-cancers-11-01574" ref-type="bibr">114</xref>,<xref rid="B115-cancers-11-01574" ref-type="bibr">115</xref>,<xref rid="B116-cancers-11-01574" ref-type="bibr">116</xref>]. Similarly, the secretion of Arginase 2 by CAFs can deplete arginine in the tumor microenvironment and impair T cell proliferation and function [<xref rid="B117-cancers-11-01574" ref-type="bibr">117</xref>,<xref rid="B118-cancers-11-01574" ref-type="bibr">118</xref>,<xref rid="B119-cancers-11-01574" ref-type="bibr">119</xref>]. Nutrient competition, however, does not only involve the subtraction of these two amino acids from the microenvironment but can also involve glucose deprivation by high-consuming cancer cells, with consequent glucose deprivation of antitumor effector T cells [<xref rid="B120-cancers-11-01574" ref-type="bibr">120</xref>,<xref rid="B121-cancers-11-01574" ref-type="bibr">121</xref>].</p></sec><sec id="sec5dot2-cancers-11-01574"><title>5.2. Endothelial Cells</title><p>Within a tumor, the increasing demand for oxygen, combined with the establishment of regional hypoxia, strongly drives the formation of new blood vessels from pre-existing ones through the tightly regulated process of angiogenesis [<xref rid="B122-cancers-11-01574" ref-type="bibr">122</xref>]. Energy-rich metabolites present in the tumor microenvironment are among the stimuli that can trigger angiogenesis. For example, lactate produced by cancer cells can be uptaken directly by endothelial cells through the MCT1 transporter and stimulate tumor angiogenesis by fueling the TCA cycle and inducing an autocrine NF-&#x003ba;B/IL-8 pathway [<xref rid="B123-cancers-11-01574" ref-type="bibr">123</xref>,<xref rid="B124-cancers-11-01574" ref-type="bibr">124</xref>]. In addition, lactate acts as a proangiogenic factor by binding and stabilizing NDRG3 (N-MYC downstream-regulated gene 3), which in turn triggers angiogenic signals during hypoxia [<xref rid="B125-cancers-11-01574" ref-type="bibr">125</xref>].</p><p>The metabolic profile of tumor-associated endothelial cells has not yet been fully elucidated; however, endothelial cell metabolism has recently become a subject of intense investigation. Multiple studies have led to the discovery that the transition of endothelial cells from a quiescent to an angiogenic profile is accompanied by a defined metabolic switch that plays a fundamental role in regulating endothelial cell function during angiogenesis. Endothelial cells are highly dependent on glycolysis rather than oxidative phosphorylation for their ATP production, and further upregulation of glycolysis occurs during angiogenesis [<xref rid="B126-cancers-11-01574" ref-type="bibr">126</xref>]. The preference by endothelial cells for aerobic glycolysis seems counter-intuitive given their direct exposure to blood and oxygen, but this phenomenon has been explained by various mechanisms: (1) by consuming less oxygen, endothelial cells leave more oxygen available to transfer into the tissue; (2) angiogenesis intrinsically requires the formation of new blood vessels in non-vascularized tissues, which is best supported by cells that can rely on anaerobic glycolysis; (3) energy production by glycolysis is faster than oxidative phosphorylation; and (4) by limiting oxidative phosphorylation, endothelial cells are also limiting the formation of ROS [<xref rid="B126-cancers-11-01574" ref-type="bibr">126</xref>].</p><p>The glycolytic activator PFKFB3 was shown to regulate not only endothelial cell proliferation but also cytoskeletal rearrangements required for vessel sprouting, and the inhibition of PFKFB3 was shown to reduce pathological ocular angiogenesis and normalize tumor vessels, improving chemotherapy and inhibiting metastasis [<xref rid="B126-cancers-11-01574" ref-type="bibr">126</xref>,<xref rid="B127-cancers-11-01574" ref-type="bibr">127</xref>,<xref rid="B128-cancers-11-01574" ref-type="bibr">128</xref>]. Oxidation of fatty acids (FAO) has also recently been reported to sustain the proliferation of endothelial cells involved in vessel sprouting by providing a source of carbon for de novo synthesis of nucleotides for DNA replication [<xref rid="B129-cancers-11-01574" ref-type="bibr">129</xref>]. Genetic and pharmacological inhibition of CPT1A, an FAO rate-limiting acyl-CoA mitochondrial transporter, has been shown to improve pathological ocular angiogenesis by the proliferation of endothelial cells [<xref rid="B129-cancers-11-01574" ref-type="bibr">129</xref>], but further studies will be needed to elucidate whether it is conceivable to apply this therapeutic strategy to target tumor angiogenesis. Interestingly, quiescent endothelial cells present 3-fold higher FAO compared to proliferating cells, and FAO has a protective role in sustaining the TCA cycle for redox homeostasis through NADPH regeneration [<xref rid="B130-cancers-11-01574" ref-type="bibr">130</xref>]. Inhibition of FAO induces a dysfunctional endothelial cell phenotype [<xref rid="B130-cancers-11-01574" ref-type="bibr">130</xref>] and a pathological mesenchymal profile [<xref rid="B131-cancers-11-01574" ref-type="bibr">131</xref>,<xref rid="B132-cancers-11-01574" ref-type="bibr">132</xref>], suggesting that FAO is required for the maintenance of endothelial cell identity.</p><p>Recent investigations have uncovered important contributions of amino acids, particularly glutamine, in the regulation of endothelial cell metabolism and function. Glutamine metabolism is required for endothelial cell proliferation [<xref rid="B133-cancers-11-01574" ref-type="bibr">133</xref>,<xref rid="B134-cancers-11-01574" ref-type="bibr">134</xref>], and although the specific role of glutamine in regulating tumor angiogenesis has not yet been characterized, depletion of glutamine levels in the tumor microenvironment through inhibition of glutamine synthase in tumor-associated macrophages resulted in tumor vessel normalization and decreased metastasis [<xref rid="B135-cancers-11-01574" ref-type="bibr">135</xref>]. Glutamine synthase has also been recently described to exert a role in endothelial cell migration by regulating Rho GTPases during pathological angiogenesis [<xref rid="B136-cancers-11-01574" ref-type="bibr">136</xref>]. Although our comprehension of the metabolic changes associated with endothelial cells and angiogenesis during tumor development is still in its infancy, all the emerging work clearly indicates that targeting the metabolism of endothelial cells may represent a promising therapeutic strategy to inhibit tumor angiogenesis.</p></sec></sec><sec id="sec6-cancers-11-01574"><title>6. Metabolic Heterogeneity of Cancer Treatment Responses</title><p>Differences in the metabolic flux between normal and tumor cells represent dependencies that can be exploited to specifically target cancer cells [<xref rid="B38-cancers-11-01574" ref-type="bibr">38</xref>]. Metabolic rewiring and redox balance maintenance constitute the result of finely tuned and interconnected molecular and metabolic pathways that have been selected to bestow human cells with the ability to react and adapt to external changes quickly. Tumors exploit this metabolic flexibility to escape environmental pressures, including drug treatment, which has recently been demonstrated by the inefficiency of cancer metabolism therapies [<xref rid="B137-cancers-11-01574" ref-type="bibr">137</xref>,<xref rid="B138-cancers-11-01574" ref-type="bibr">138</xref>]. Indeed, cancer cells have proven to be extremely plastic with regard to metabolism, and during tumor progression or in response to stressors, they are able to switch between alternative metabolic phenotypes, like glycolysis and oxidative phosphorylation [<xref rid="B40-cancers-11-01574" ref-type="bibr">40</xref>].</p><p>These distinct metabolic states of glycolytic versus oxidative are governed and coordinated by master regulators, such as AMP-activated protein kinase (AMPK) and HIF-1, which act as molecular rheostats guiding intracellular adaptations to external perturbations [<xref rid="B139-cancers-11-01574" ref-type="bibr">139</xref>]. However, thanks to experimentally validated model predictions, it has recently been demonstrated that cancer cells have the ability to adopt additional metabolic states not typical of normal cells, challenging the conventional dichotomous classification of tumor metabolism [<xref rid="B140-cancers-11-01574" ref-type="bibr">140</xref>]. To manage this complexity, several frameworks have been constructed that aim to reduce the size of an extensive regulatory circuit to basic components, and yet capture its fundamental principles and overall network behavior [<xref rid="B138-cancers-11-01574" ref-type="bibr">138</xref>,<xref rid="B141-cancers-11-01574" ref-type="bibr">141</xref>,<xref rid="B142-cancers-11-01574" ref-type="bibr">142</xref>]. Leveraging such metabolic network-deconvolution strategies has identified multiple genes/proteins that can predict cancer drug response or resistance [<xref rid="B143-cancers-11-01574" ref-type="bibr">143</xref>,<xref rid="B144-cancers-11-01574" ref-type="bibr">144</xref>,<xref rid="B145-cancers-11-01574" ref-type="bibr">145</xref>,<xref rid="B146-cancers-11-01574" ref-type="bibr">146</xref>]. For instance, as a central carbon source for the cell, glucose metabolism is highly articulated. Many enzymes contribute to the series of reactions necessary to catabolize glucose, and some key components of the glycolytic pathway, such as glucose transporters (GLUTs), hexokinase (HK), pyruvate kinase M2 (PKM2), and LDHA, have been selectively exploited to enable glycolytic inhibition as an anticancer strategy [<xref rid="B147-cancers-11-01574" ref-type="bibr">147</xref>,<xref rid="B148-cancers-11-01574" ref-type="bibr">148</xref>,<xref rid="B149-cancers-11-01574" ref-type="bibr">149</xref>,<xref rid="B150-cancers-11-01574" ref-type="bibr">150</xref>,<xref rid="B151-cancers-11-01574" ref-type="bibr">151</xref>]. Similarly, dichloroacetate is a pyruvate dehydrogenase kinase (PDK) inhibitor that is being explored clinically with promising results [<xref rid="B152-cancers-11-01574" ref-type="bibr">152</xref>,<xref rid="B153-cancers-11-01574" ref-type="bibr">153</xref>]. By inhibiting PDK and, subsequently, pyruvate dehydrogenase (PDH), the rate-limiting step between glycolysis and the TCA cycle can be targeted to flip a metabolic switch from glycolysis to mitochondrial respiration and induce apoptosis.</p><p>Two additional key metabolic pathways that have been extensively dissected to identify optimal points of intervention are the fatty acid biosynthesis pathway, which synthesizes lipid synthesis from basic metabolites like acetyl-CoA and malonyl-CoA, and glutaminolysis, which regulates cell growth and energy metabolism by converting glutamine to &#x003b1;-ketoglutarate (&#x003b1;-KG). To target fatty acid biosynthesis, fatty acid synthase (FASN) has emerged as a promising anticancer target. FASN inhibitors may sensitize cells to chemotherapy or enhance the efficacy of other targeted therapies [<xref rid="B154-cancers-11-01574" ref-type="bibr">154</xref>,<xref rid="B155-cancers-11-01574" ref-type="bibr">155</xref>], and several FASN inhibitors have shown single-agent antitumor activity [<xref rid="B156-cancers-11-01574" ref-type="bibr">156</xref>,<xref rid="B157-cancers-11-01574" ref-type="bibr">157</xref>]. Small molecule inhibitors of glutaminase (GLS) effectively shut down glutaminolysis, which plays a critical role in tumor cell metabolism, and several GLS inhibitors are in various stages of pre-clinical or clinical development [<xref rid="B46-cancers-11-01574" ref-type="bibr">46</xref>,<xref rid="B158-cancers-11-01574" ref-type="bibr">158</xref>,<xref rid="B159-cancers-11-01574" ref-type="bibr">159</xref>,<xref rid="B160-cancers-11-01574" ref-type="bibr">160</xref>].</p><p>To maximize the clinical impact of the growing list of metabolic inhibitors in oncology practice, it is essential that we continue to expand our understanding of tumor metabolic profiles, heterogeneity, and adaptive response [<xref rid="B143-cancers-11-01574" ref-type="bibr">143</xref>,<xref rid="B161-cancers-11-01574" ref-type="bibr">161</xref>]. In some cases, the presence of dominant drivers or tumor suppressor mutations that dysregulate metabolic pathways provides useful context to select treatment. For example, the antitumor activity of caloric restriction appears to be entirely abrogated by the activation of PI3K or inactivation of PTEN [<xref rid="B162-cancers-11-01574" ref-type="bibr">162</xref>]. Similarly, while dietary restriction of glucose can inhibit the growth of many cancers, in some contexts, such as in the absence of an isoform of protein kinase C or in the presence of certain mutant p53 alleles, glucose restriction can paradoxically lead to more aggressive tumors [<xref rid="B163-cancers-11-01574" ref-type="bibr">163</xref>,<xref rid="B164-cancers-11-01574" ref-type="bibr">164</xref>]. However, as discussed above, there exists a vast spectrum of specific metabolic programs both among tumors and within a single tumor. How, then, can specific metabolic programs be identified to uncover therapeutically relevant dependencies? PET imaging can measure glucose uptake by tumor cells, but it does not output functional information regarding the utilization of metabolic pathways inside the cells [<xref rid="B165-cancers-11-01574" ref-type="bibr">165</xref>]. Other noninvasive approaches, such as magnetic resonance spectroscopy (MRS), which can measure metabolite concentrations in tumors, combined with metabolomic profiling of serum or urine, may produce a data package that can guide the selection of appropriate targeted therapy(ies) in a tumor- or patient-specific fashion [<xref rid="B166-cancers-11-01574" ref-type="bibr">166</xref>,<xref rid="B167-cancers-11-01574" ref-type="bibr">167</xref>]. Additionally, tools such as nanoproteomic assays could be developed to monitor target gene expression and quantify signaling in rare tumor cell populations, and such has already been accomplished for AKT1/2/3 and 4EBP1 in acute myeloid leukemia cells [<xref rid="B168-cancers-11-01574" ref-type="bibr">168</xref>].</p><p>Both pre-clinical and clinical studies are clear that even effective targeted metabolic therapies cannot produce durable disease remissions or cures, and understanding how cancer cells rewire their metabolism under pressure&#x02014;how &#x0201c;compensatory&#x0201d; metabolism negatively impacts treatment responses&#x02014;is an area of intense investigation [<xref rid="B145-cancers-11-01574" ref-type="bibr">145</xref>]. As a very direct example of this, the use of mitochondrial inhibitors such as oligomycin induces a glycolytic phenotype, whereas glycolytic inhibitors enhance the activity of AMPK and induce an oxidative phenotype [<xref rid="B169-cancers-11-01574" ref-type="bibr">169</xref>]. This metabolic plasticity can be thwarted with dual inhibition of both glycolytic and mitochondrial respiration, as clearly exemplified by a recent study in which the authors elegantly demonstrated that metformin plus fasting-induced hypoglycemia synergistically impacts tumor growth [<xref rid="B170-cancers-11-01574" ref-type="bibr">170</xref>]. Other recent studies have shown that a subset of BRAF-mutated melanoma cells that are resistant to BRAF inhibitors can activate the MITF-driven expression of PGC1a to upregulate mitochondrial respiration to evade therapy [<xref rid="B171-cancers-11-01574" ref-type="bibr">171</xref>]. This phenomenon has been observed upon MEK or PI3K inhibitor treatment in oncogenic KRAS-driven tumors, such as pancreatic cancer, as well [<xref rid="B79-cancers-11-01574" ref-type="bibr">79</xref>]. Moreover, there are data to support that the effects of BRAF inhibition are maximized when melanoma cells are heavily reliant on glycolysis and/or when depletion of mitochondria forces cells to solely utilize glycolysis [<xref rid="B172-cancers-11-01574" ref-type="bibr">172</xref>]. Together, these studies suggest identifying and targeting the major compensatory metabolic pathways induced upon drug treatment can enhance therapeutic benefits by illuminating rational drug combinations. Such approaches are also certain to contribute to our ability to profile patient tumors in real-time to deliver personalized therapeutic regimens.</p><p>The effectiveness of metabolic or cytotoxic therapies is strongly influenced by spatial heterogeneity with regard to both the tumor structure/microenvironment and drug diffusion [<xref rid="B173-cancers-11-01574" ref-type="bibr">173</xref>]. For example, selective intratumoral lethality, or intra-tumor metabolic zonation, is a recently described phenomenon in which a drug selectively kills less aggressive clones while sparing more malignant populations based on their relative distance from blood vessels, and it has been confirmed to affect antitumor drug effects in a majority of solid tumors [<xref rid="B174-cancers-11-01574" ref-type="bibr">174</xref>,<xref rid="B175-cancers-11-01574" ref-type="bibr">175</xref>]. Similarly, acidification of intratumoral regions by cytotoxic agents or due to proximity to areas where extensive cell death has occurred can mediate invasion by metabolically distinct neighbor clones and impose selective pressure to define tumor evolution [<xref rid="B176-cancers-11-01574" ref-type="bibr">176</xref>,<xref rid="B177-cancers-11-01574" ref-type="bibr">177</xref>].</p></sec><sec id="sec7-cancers-11-01574"><title>7. Concluding Remarks</title><p>Our knowledge of the mechanisms by which phenotypic, temporal, spatial, and molecular heterogeneity influence tumor growth and drug response, represent decades of attempts to deliver pharmacological cures to patients with cancer. It is clear that one of the greatest challenges in current oncology practice is to develop methods to characterize and exploit the metabolic and other cancer-specific programs that endow tumors with the ability to adapt to and evade therapeutic assault. By understanding the highly heterogeneous and plastic microenvironment of tumors, and through continued characterization of oncogenic reprogramming of cancer cells across tumor types, we can aim toward the development of biomarkers and techniques that can support the real-time analysis of clinical samples to design personalized therapeutic drug regimens. Undoubtedly, targeting the multitude of potential metabolic strategies that tumors can activate will play an essential role in these efforts as the field continues to push forward.</p></sec></body><back><ack><title>Acknowledgments</title><p>Authors would like to thank ECHO&#x02014;Cultural Heritage Online&#x02014;Open Access Infrastructure for a Future Web of Culture and Science (<uri xlink:href="http://echo.mpiwg-berlin.mpg.de/home">http://echo.mpiwg-berlin.mpg.de/home</uri>) for the content of <xref ref-type="fig" rid="cancers-11-01574-f001">Figure 1</xref> reproduced from <italic>Ueber den feinern Bau und die Formen der krankhaften Geschw&#x000fc;lste</italic> [<xref rid="B1-cancers-11-01574" ref-type="bibr">1</xref>] and Lisa M. Becker for helping with the translation of figure captions. The authors would like to thank Chieh-Yuan Li, I-Lin Ho, Er-Yen Yen and Hong Jiang for continuing to improve the CRTs platform.</p></ack><notes><title>Author Contributions</title><p>S.L. (Sara Loponte) and S.L. (Sara Lovisa) contributed equally to the writing of the manuscript, A.K.D. provided scientific feedback and edited the manuscript, A.C. and A.V. wrote the manuscript and coordinated the work.</p></notes><notes><title>Funding</title><p>This study was supported by the Andrew Sabin Family Fellowship Award, UT MD Anderson Cancer Center Pancreatic Cancer Moon Shot and UT MD Anderson Cancer Center Start-Up Funds to A.V.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-cancers-11-01574"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>J.</given-names></name></person-group><source>Ueber den Feinern Bau und die Formen der Krankhaften Geschw&#x000fc;lste</source><publisher-name>G. Reimer</publisher-name><publisher-loc>Berlin, Germany</publisher-loc><year>1838</year></element-citation></ref><ref id="B2-cancers-11-01574"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>J.</given-names></name></person-group><article-title>On the nature and structural characteristics of cancer: General observations on the minute structure of morbid growths</article-title><source>CA Cancer J. Clin.</source><year>1973</year><volume>23</volume><fpage>307</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.3322/canjclin.23.5.307</pub-id></element-citation></ref><ref id="B3-cancers-11-01574"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajdu</surname><given-names>S.I.</given-names></name></person-group><article-title>A note from history: The first tumor pathologist</article-title><source>Ann. Clin. Lab. Sci.</source><year>2004</year><volume>34</volume><fpage>355</fpage><lpage>356</lpage><?supplied-pmid 15487713?><pub-id pub-id-type="pmid">15487713</pub-id></element-citation></ref><ref id="B4-cancers-11-01574"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Virchow</surname><given-names>R.</given-names></name></person-group><source>Cellular Pathology as Based upon Physiological and Pathological Histology</source><publisher-name>J. B. Lippincott</publisher-name><publisher-loc>Philadelphia, PA, USA</publisher-loc><year>1863</year><pub-id pub-id-type="doi">10.5962/bhl.title.32770</pub-id></element-citation></ref><ref id="B5-cancers-11-01574"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>G.A.</given-names></name></person-group><article-title>Virchow, the heroic model in medicine: Health policy by accolade</article-title><source>Am. J. Public Health</source><year>1987</year><volume>77</volume><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.2105/AJPH.77.1.82</pub-id><?supplied-pmid 3538915?><pub-id pub-id-type="pmid">3538915</pub-id></element-citation></ref><ref id="B6-cancers-11-01574"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furth</surname><given-names>J.</given-names></name></person-group><article-title>The Transmission of Leukemia of Mice with a Single Cell</article-title><source>Cancer Res.</source><year>1937</year><volume>31</volume><fpage>276</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1158/ajc.1937.276</pub-id></element-citation></ref><ref id="B7-cancers-11-01574"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Southam</surname><given-names>C.</given-names></name></person-group><article-title>Quantitative studies of autotransplantation of human cancer</article-title><source>Cancer</source><year>1961</year><volume>14</volume><fpage>971</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(196109/10)14:5&#x0003c;971::AID-CNCR2820140510&#x0003e;3.0.CO;2-O</pub-id></element-citation></ref><ref id="B8-cancers-11-01574"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dick</surname><given-names>J.E.</given-names></name></person-group><article-title>Stem cell concepts renew cancer research</article-title><source>Blood</source><year>2008</year><volume>112</volume><fpage>4793</fpage><lpage>4807</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-08-077941</pub-id><pub-id pub-id-type="pmid">19064739</pub-id></element-citation></ref><ref id="B9-cancers-11-01574"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fearon</surname><given-names>E.R.</given-names></name><name><surname>Hamilton</surname><given-names>S.R.</given-names></name><name><surname>Vogelstein</surname><given-names>B.</given-names></name></person-group><article-title>Clonal analysis of human colorectal tumors</article-title><source>Science</source><year>1987</year><volume>238</volume><fpage>193</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1126/science.2889267</pub-id><pub-id pub-id-type="pmid">2889267</pub-id></element-citation></ref><ref id="B10-cancers-11-01574"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowell</surname><given-names>P.C.</given-names></name></person-group><article-title>The clonal evolution of tumor cell populations</article-title><source>Science</source><year>1976</year><volume>194</volume><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1126/science.959840</pub-id><pub-id pub-id-type="pmid">959840</pub-id></element-citation></ref><ref id="B11-cancers-11-01574"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dexter</surname><given-names>D.L.</given-names></name><name><surname>Kowalski</surname><given-names>H.M.</given-names></name><name><surname>Blazar</surname><given-names>B.A.</given-names></name><name><surname>Fligiel</surname><given-names>Z.</given-names></name><name><surname>Vogel</surname><given-names>R.</given-names></name><name><surname>Heppner</surname><given-names>G.H.</given-names></name></person-group><article-title>Heterogeneity of tumor cells from a single mouse mammary tumor</article-title><source>Cancer Res.</source><year>1978</year><volume>38</volume><fpage>3174</fpage><lpage>3181</lpage><pub-id pub-id-type="pmid">210930</pub-id></element-citation></ref><ref id="B12-cancers-11-01574"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabresi</surname><given-names>P.</given-names></name><name><surname>Dexter</surname><given-names>D.L.</given-names></name><name><surname>Heppner</surname><given-names>G.H.</given-names></name></person-group><article-title>Clinical and pharmacological implications of cancer cell differentiation and heterogeneity</article-title><source>Biochem. Pharmacol.</source><year>1979</year><volume>28</volume><fpage>1933</fpage><lpage>1941</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(79)90647-6</pub-id><pub-id pub-id-type="pmid">454465</pub-id></element-citation></ref><ref id="B13-cancers-11-01574"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hager</surname><given-names>J.C.</given-names></name><name><surname>Heppner</surname><given-names>G.H.</given-names></name></person-group><article-title>Heterogeneity of expression and induction of mouse mammary tumor virus antigens in mouse mammary tumors</article-title><source>Cancer Res.</source><year>1982</year><volume>42</volume><fpage>4325</fpage><lpage>4329</lpage><?supplied-pmid 6290031?><pub-id pub-id-type="pmid">6290031</pub-id></element-citation></ref><ref id="B14-cancers-11-01574"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heppner</surname><given-names>G.H.</given-names></name><name><surname>Dexter</surname><given-names>D.L.</given-names></name><name><surname>DeNucci</surname><given-names>T.</given-names></name><name><surname>Miller</surname><given-names>F.R.</given-names></name><name><surname>Calabresi</surname><given-names>P.</given-names></name></person-group><article-title>Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor</article-title><source>Cancer Res.</source><year>1978</year><volume>38</volume><fpage>3758</fpage><lpage>3763</lpage><?supplied-pmid 698935?><pub-id pub-id-type="pmid">698935</pub-id></element-citation></ref><ref id="B15-cancers-11-01574"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>B.E.</given-names></name><name><surname>Miller</surname><given-names>F.R.</given-names></name><name><surname>Leith</surname><given-names>J.</given-names></name><name><surname>Heppner</surname><given-names>G.H.</given-names></name></person-group><article-title>Growth interaction in vivo between tumor subpopulations derived from a single mouse mammary tumor</article-title><source>Cancer Res.</source><year>1980</year><volume>40</volume><fpage>3977</fpage><lpage>3981</lpage><pub-id pub-id-type="pmid">7471048</pub-id></element-citation></ref><ref id="B16-cancers-11-01574"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>B.E.</given-names></name><name><surname>Miller</surname><given-names>F.R.</given-names></name><name><surname>Wilburn</surname><given-names>D.</given-names></name><name><surname>Heppner</surname><given-names>G.H.</given-names></name></person-group><article-title>Dominance of a tumor subpopulation line in mixed heterogeneous mouse mammary tumors</article-title><source>Cancer Res.</source><year>1988</year><volume>48</volume><fpage>5747</fpage><lpage>5753</lpage><?supplied-pmid 3167832?><pub-id pub-id-type="pmid">3167832</pub-id></element-citation></ref><ref id="B17-cancers-11-01574"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>F.R.</given-names></name><name><surname>Heppner</surname><given-names>G.H.</given-names></name></person-group><article-title>Immunologic heterogeneity of tumor cell subpopulations from a single mouse mammary tumor</article-title><source>J. Natl. Cancer Inst.</source><year>1979</year><volume>63</volume><fpage>1457</fpage><lpage>1463</lpage><?supplied-pmid 229294?><pub-id pub-id-type="pmid">229294</pub-id></element-citation></ref><ref id="B18-cancers-11-01574"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashina</surname><given-names>K.</given-names></name><name><surname>Heppner</surname><given-names>G.H.</given-names></name></person-group><article-title>Correlation of frequency of induced mutation and metastatic potential in tumor cell lines from a single mouse mammary tumor</article-title><source>Cancer Res.</source><year>1985</year><volume>45</volume><fpage>4015</fpage><lpage>4019</lpage><?supplied-pmid 4027998?><pub-id pub-id-type="pmid">4027998</pub-id></element-citation></ref><ref id="B19-cancers-11-01574"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heppner</surname><given-names>G.H.</given-names></name></person-group><article-title>Tumor heterogeneity</article-title><source>Cancer Res.</source><year>1984</year><volume>44</volume><fpage>2259</fpage><lpage>2265</lpage><pub-id pub-id-type="pmid">6372991</pub-id></element-citation></ref><ref id="B20-cancers-11-01574"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welch</surname><given-names>D.R.</given-names></name></person-group><article-title>Tumor Heterogeneity&#x02014;A &#x02018;Contemporary Concept&#x02019; Founded on Historical Insights and Predictions</article-title><source>Cancer Res.</source><year>2016</year><volume>76</volume><fpage>4</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-3024</pub-id><pub-id pub-id-type="pmid">26729788</pub-id></element-citation></ref><ref id="B21-cancers-11-01574"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foulds</surname><given-names>L.</given-names></name></person-group><article-title>The natural history of cancer</article-title><source>J. Chronic Dis.</source><year>1958</year><volume>8</volume><fpage>2</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/0021-9681(58)90039-0</pub-id><pub-id pub-id-type="pmid">13563591</pub-id></element-citation></ref><ref id="B22-cancers-11-01574"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fearon</surname><given-names>E.R.</given-names></name><name><surname>Vogelstein</surname><given-names>B.</given-names></name></person-group><article-title>A genetic model for colorectal tumorigenesis</article-title><source>Cell</source><year>1990</year><volume>61</volume><fpage>759</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(90)90186-I</pub-id><pub-id pub-id-type="pmid">2188735</pub-id></element-citation></ref><ref id="B23-cancers-11-01574"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>A.</given-names></name><name><surname>Gao</surname><given-names>R.</given-names></name><name><surname>Navin</surname><given-names>N.</given-names></name></person-group><article-title>Tumor evolution: Linear, branching, neutral or punctuated?</article-title><source>Biochim. Biophys. Acta Rev. Cancer</source><year>2017</year><volume>1867</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2017.01.003</pub-id><?supplied-pmid 28110020?><pub-id pub-id-type="pmid">28110020</pub-id></element-citation></ref><ref id="B24-cancers-11-01574"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGranahan</surname><given-names>N.</given-names></name><name><surname>Swanton</surname><given-names>C.</given-names></name></person-group><article-title>Biological and therapeutic impact of intratumor heterogeneity in cancer evolution</article-title><source>Cancer Cell</source><year>2015</year><volume>27</volume><fpage>15</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2014.12.001</pub-id><?supplied-pmid 25584892?><pub-id pub-id-type="pmid">25584892</pub-id></element-citation></ref><ref id="B25-cancers-11-01574"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>L.C.</given-names></name><name><surname>Torres</surname><given-names>M.</given-names></name><name><surname>Real</surname><given-names>F.X.</given-names></name></person-group><article-title>Somatic mosaicism: On the road to cancer</article-title><source>Nat. Rev. Cancer</source><year>2016</year><volume>16</volume><fpage>43</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/nrc.2015.1</pub-id><?supplied-pmid 26678315?><pub-id pub-id-type="pmid">26678315</pub-id></element-citation></ref><ref id="B26-cancers-11-01574"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>R.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Curtis</surname><given-names>C.</given-names></name></person-group><article-title>Big Bang Tumor Growth and Clonal Evolution</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2018</year><volume>8</volume><fpage>a028381</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a028381</pub-id><?supplied-pmid 28710260?><pub-id pub-id-type="pmid">28710260</pub-id></element-citation></ref><ref id="B27-cancers-11-01574"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.Z.</given-names></name><name><surname>Spektor</surname><given-names>A.</given-names></name><name><surname>Cornils</surname><given-names>H.</given-names></name><name><surname>Francis</surname><given-names>J.M.</given-names></name><name><surname>Jackson</surname><given-names>E.K.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Meyerson</surname><given-names>M.</given-names></name><name><surname>Pellman</surname><given-names>D.</given-names></name></person-group><article-title>Chromothripsis from DNA damage in micronuclei</article-title><source>Nature</source><year>2015</year><volume>522</volume><fpage>179</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1038/nature14493</pub-id><pub-id pub-id-type="pmid">26017310</pub-id></element-citation></ref><ref id="B28-cancers-11-01574"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>R.</given-names></name><name><surname>Davis</surname><given-names>A.</given-names></name><name><surname>McDonald</surname><given-names>T.O.</given-names></name><name><surname>Sei</surname><given-names>E.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Tsai</surname><given-names>P.C.</given-names></name><name><surname>Casasent</surname><given-names>A.</given-names></name><name><surname>Waters</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Punctuated copy number evolution and clonal stasis in triple-negative breast cancer</article-title><source>Nat. Genet.</source><year>2016</year><volume>48</volume><fpage>1119</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1038/ng.3641</pub-id><pub-id pub-id-type="pmid">27526321</pub-id></element-citation></ref><ref id="B29-cancers-11-01574"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sottoriva</surname><given-names>A.</given-names></name><name><surname>Kang</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Graham</surname><given-names>T.A.</given-names></name><name><surname>Salomon</surname><given-names>M.P.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Marjoram</surname><given-names>P.</given-names></name><name><surname>Siegmund</surname><given-names>K.</given-names></name><name><surname>Press</surname><given-names>M.F.</given-names></name><name><surname>Shibata</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A Big Bang model of human colorectal tumor growth</article-title><source>Nat. Genet.</source><year>2015</year><volume>47</volume><fpage>209</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/ng.3214</pub-id><pub-id pub-id-type="pmid">25665006</pub-id></element-citation></ref><ref id="B30-cancers-11-01574"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marusyk</surname><given-names>A.</given-names></name><name><surname>Tabassum</surname><given-names>D.P.</given-names></name><name><surname>Altrock</surname><given-names>P.M.</given-names></name><name><surname>Almendro</surname><given-names>V.</given-names></name><name><surname>Michor</surname><given-names>F.</given-names></name><name><surname>Polyak</surname><given-names>K.</given-names></name></person-group><article-title>Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity</article-title><source>Nature</source><year>2014</year><volume>514</volume><fpage>54</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1038/nature13556</pub-id><pub-id pub-id-type="pmid">25079331</pub-id></element-citation></ref><ref id="B31-cancers-11-01574"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seth</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>C.Y.</given-names></name><name><surname>Ho</surname><given-names>I.L.</given-names></name><name><surname>Corti</surname><given-names>D.</given-names></name><name><surname>Loponte</surname><given-names>S.</given-names></name><name><surname>Sapio</surname><given-names>L.</given-names></name><name><surname>Del Poggetto</surname><given-names>E.</given-names></name><name><surname>Yen</surname><given-names>E.Y.</given-names></name><name><surname>Robinson</surname><given-names>F.S.</given-names></name><name><surname>Peoples</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors</article-title><source>Cell Rep.</source><year>2019</year><volume>26</volume><fpage>1518</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.01.048</pub-id><pub-id pub-id-type="pmid">30726735</pub-id></element-citation></ref><ref id="B32-cancers-11-01574"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallaher</surname><given-names>J.A.</given-names></name><name><surname>Enriquez-Navas</surname><given-names>P.M.</given-names></name><name><surname>Luddy</surname><given-names>K.A.</given-names></name><name><surname>Gatenby</surname><given-names>R.A.</given-names></name><name><surname>Anderson</surname><given-names>A.R.A.</given-names></name></person-group><article-title>Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies</article-title><source>Cancer Res.</source><year>2018</year><volume>78</volume><fpage>2127</fpage><lpage>2139</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-2649</pub-id><pub-id pub-id-type="pmid">29382708</pub-id></element-citation></ref><ref id="B33-cancers-11-01574"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y.</given-names></name></person-group><article-title>Spatial Heterogeneity in the Tumor Microenvironment</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2016</year><volume>6</volume><fpage>a026583</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a026583</pub-id><?supplied-pmid 27481837?><pub-id pub-id-type="pmid">27481837</pub-id></element-citation></ref><ref id="B34-cancers-11-01574"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viale</surname><given-names>A.</given-names></name><name><surname>Corti</surname><given-names>D.</given-names></name><name><surname>Draetta</surname><given-names>G.F.</given-names></name></person-group><article-title>Tumors and Mitochondrial Respiration: A Neglected Connection</article-title><source>Cancer Res.</source><year>2015</year><volume>75</volume><fpage>3687</fpage><lpage>3691</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-0491</pub-id><?supplied-pmid 26374463?><pub-id pub-id-type="pmid">26374463</pub-id></element-citation></ref><ref id="B35-cancers-11-01574"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warburg</surname><given-names>O.</given-names></name></person-group><article-title>On the origin of cancer cells</article-title><source>Science (New York N.Y.)</source><year>1956</year><volume>123</volume><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1126/science.123.3191.309</pub-id><?supplied-pmid 13298683?><pub-id pub-id-type="pmid">13298683</pub-id></element-citation></ref><ref id="B36-cancers-11-01574"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warburg</surname><given-names>O.</given-names></name><name><surname>Wind</surname><given-names>F.</given-names></name><name><surname>Negelein</surname><given-names>E.</given-names></name></person-group><article-title>The Metabolism of Tumors in the Body</article-title><source>J. Gen. Physiol.</source><year>1927</year><volume>8</volume><fpage>519</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1085/jgp.8.6.519</pub-id><?supplied-pmid 19872213?><pub-id pub-id-type="pmid">19872213</pub-id></element-citation></ref><ref id="B37-cancers-11-01574"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Heiden</surname><given-names>M.G.</given-names></name><name><surname>Cantley</surname><given-names>L.C.</given-names></name><name><surname>Thompson</surname><given-names>C.B.</given-names></name></person-group><article-title>Understanding the Warburg effect: The metabolic requirements of cell proliferation</article-title><source>Science</source><year>2009</year><volume>324</volume><fpage>1029</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1126/science.1160809</pub-id><?supplied-pmid 19460998?><pub-id pub-id-type="pmid">19460998</pub-id></element-citation></ref><ref id="B38-cancers-11-01574"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantor</surname><given-names>J.R.</given-names></name><name><surname>Sabatini</surname><given-names>D.M.</given-names></name></person-group><article-title>Cancer cell metabolism: One hallmark, many faces</article-title><source>Cancer Discov.</source><year>2012</year><volume>2</volume><fpage>881</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0345</pub-id><pub-id pub-id-type="pmid">23009760</pub-id></element-citation></ref><ref id="B39-cancers-11-01574"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>C.V.</given-names></name></person-group><article-title>MYC, metabolism, cell growth, and tumorigenesis</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2013</year><volume>3</volume><fpage>a014217</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a014217</pub-id><pub-id pub-id-type="pmid">23906881</pub-id></element-citation></ref><ref id="B40-cancers-11-01574"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBerardinis</surname><given-names>R.J.</given-names></name><name><surname>Lum</surname><given-names>J.J.</given-names></name><name><surname>Hatzivassiliou</surname><given-names>G.</given-names></name><name><surname>Thompson</surname><given-names>C.B.</given-names></name></person-group><article-title>The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation</article-title><source>Cell Metab.</source><year>2008</year><volume>7</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2007.10.002</pub-id><pub-id pub-id-type="pmid">18177721</pub-id></element-citation></ref><ref id="B41-cancers-11-01574"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koppenol</surname><given-names>W.H.</given-names></name><name><surname>Bounds</surname><given-names>P.L.</given-names></name><name><surname>Dang</surname><given-names>C.V.</given-names></name></person-group><article-title>Otto Warburg&#x02019;s contributions to current concepts of cancer metabolism</article-title><source>Nat. Rev. Cancer</source><year>2011</year><volume>11</volume><fpage>325</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1038/nrc3038</pub-id><pub-id pub-id-type="pmid">21508971</pub-id></element-citation></ref><ref id="B42-cancers-11-01574"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stine</surname><given-names>Z.E.</given-names></name><name><surname>Walton</surname><given-names>Z.E.</given-names></name><name><surname>Altman</surname><given-names>B.J.</given-names></name><name><surname>Hsieh</surname><given-names>A.L.</given-names></name><name><surname>Dang</surname><given-names>C.V.</given-names></name></person-group><article-title>MYC, Metabolism, and Cancer</article-title><source>Cancer Discov.</source><year>2015</year><volume>5</volume><fpage>1024</fpage><lpage>1039</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0507</pub-id><pub-id pub-id-type="pmid">26382145</pub-id></element-citation></ref><ref id="B43-cancers-11-01574"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Heiden</surname><given-names>M.G.</given-names></name><name><surname>DeBerardinis</surname><given-names>R.J.</given-names></name></person-group><article-title>Understanding the Intersections between Metabolism and Cancer Biology</article-title><source>Cell</source><year>2017</year><volume>168</volume><fpage>657</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.12.039</pub-id><?supplied-pmid 28187287?><pub-id pub-id-type="pmid">28187287</pub-id></element-citation></ref><ref id="B44-cancers-11-01574"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schofield</surname><given-names>C.J.</given-names></name><name><surname>Ratcliffe</surname><given-names>P.J.</given-names></name></person-group><article-title>Oxygen sensing by HIF hydroxylases</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2004</year><volume>5</volume><fpage>343</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1038/nrm1366</pub-id><?supplied-pmid 15122348?><pub-id pub-id-type="pmid">15122348</pub-id></element-citation></ref><ref id="B45-cancers-11-01574"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel-Haleem</surname><given-names>A.M.</given-names></name><name><surname>Lewis</surname><given-names>N.E.</given-names></name><name><surname>Jamshidi</surname><given-names>N.</given-names></name><name><surname>Mineta</surname><given-names>K.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Gojobori</surname><given-names>T.</given-names></name></person-group><article-title>The Emerging Facets of Non-Cancerous Warburg Effect</article-title><source>Front. Endocrinol. (Lausanne)</source><year>2017</year><volume>8</volume><fpage>279</fpage><pub-id pub-id-type="doi">10.3389/fendo.2017.00279</pub-id><?supplied-pmid 29109698?><pub-id pub-id-type="pmid">29109698</pub-id></element-citation></ref><ref id="B46-cancers-11-01574"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altman</surname><given-names>B.J.</given-names></name><name><surname>Stine</surname><given-names>Z.E.</given-names></name><name><surname>Dang</surname><given-names>C.V.</given-names></name></person-group><article-title>From Krebs to clinic: Glutamine metabolism to cancer therapy</article-title><source>Nat. Rev. Cancer</source><year>2016</year><volume>16</volume><fpage>619</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.71</pub-id><pub-id pub-id-type="pmid">27492215</pub-id></element-citation></ref><ref id="B47-cancers-11-01574"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname><given-names>D.</given-names></name></person-group><article-title>MYC provides a global boost</article-title><source>Nat. Rev. Genet.</source><year>2012</year><volume>13</volume><fpage>758</fpage><pub-id pub-id-type="doi">10.1038/nrg3364</pub-id><pub-id pub-id-type="pmid">23007386</pub-id></element-citation></ref><ref id="B48-cancers-11-01574"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabo</surname><given-names>A.</given-names></name><name><surname>Kress</surname><given-names>T.R.</given-names></name><name><surname>Pelizzola</surname><given-names>M.</given-names></name><name><surname>de Pretis</surname><given-names>S.</given-names></name><name><surname>Gorski</surname><given-names>M.M.</given-names></name><name><surname>Tesi</surname><given-names>A.</given-names></name><name><surname>Morelli</surname><given-names>M.J.</given-names></name><name><surname>Bora</surname><given-names>P.</given-names></name><name><surname>Doni</surname><given-names>M.</given-names></name><name><surname>Verrecchia</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis</article-title><source>Nature</source><year>2014</year><volume>511</volume><fpage>488</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/nature13537</pub-id><pub-id pub-id-type="pmid">25043028</pub-id></element-citation></ref><ref id="B49-cancers-11-01574"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Najafov</surname><given-names>A.</given-names></name><name><surname>Alessi</surname><given-names>D.R.</given-names></name></person-group><article-title>Uncoupling the Warburg effect from cancer</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>19135</fpage><lpage>19136</lpage><pub-id pub-id-type="doi">10.1073/pnas.1014047107</pub-id><pub-id pub-id-type="pmid">21041650</pub-id></element-citation></ref><ref id="B50-cancers-11-01574"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>A.</given-names></name><name><surname>Bolanos</surname><given-names>J.P.</given-names></name><name><surname>Moncada</surname><given-names>S.</given-names></name></person-group><article-title>E3 ubiquitin ligase APC/C-Cdh1 accounts for the Warburg effect by linking glycolysis to cell proliferation</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>738</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1073/pnas.0913668107</pub-id><pub-id pub-id-type="pmid">20080744</pub-id></element-citation></ref><ref id="B51-cancers-11-01574"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>S.L.</given-names></name><name><surname>Palacios-Callender</surname><given-names>M.</given-names></name><name><surname>Frakich</surname><given-names>N.</given-names></name><name><surname>De Leon</surname><given-names>J.</given-names></name><name><surname>Schmitt</surname><given-names>C.A.</given-names></name><name><surname>Boorn</surname><given-names>L.</given-names></name><name><surname>Davis</surname><given-names>N.</given-names></name><name><surname>Moncada</surname><given-names>S.</given-names></name></person-group><article-title>Anaphase-promoting complex/cyclosome-Cdh1 coordinates glycolysis and glutaminolysis with transition to S phase in human T lymphocytes</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>18868</fpage><lpage>18873</lpage><pub-id pub-id-type="doi">10.1073/pnas.1012362107</pub-id><pub-id pub-id-type="pmid">20921411</pub-id></element-citation></ref><ref id="B52-cancers-11-01574"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bensaad</surname><given-names>K.</given-names></name><name><surname>Tsuruta</surname><given-names>A.</given-names></name><name><surname>Selak</surname><given-names>M.A.</given-names></name><name><surname>Vidal</surname><given-names>M.N.</given-names></name><name><surname>Nakano</surname><given-names>K.</given-names></name><name><surname>Bartrons</surname><given-names>R.</given-names></name><name><surname>Gottlieb</surname><given-names>E.</given-names></name><name><surname>Vousden</surname><given-names>K.H.</given-names></name></person-group><article-title>TIGAR, a p53-inducible regulator of glycolysis and apoptosis</article-title><source>Cell</source><year>2006</year><volume>126</volume><fpage>107</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.05.036</pub-id><pub-id pub-id-type="pmid">16839880</pub-id></element-citation></ref><ref id="B53-cancers-11-01574"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Lin</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Levine</surname><given-names>A.J.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name></person-group><article-title>Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>16259</fpage><lpage>16264</lpage><pub-id pub-id-type="doi">10.1073/pnas.1113884108</pub-id><?supplied-pmid 21930938?><pub-id pub-id-type="pmid">21930938</pub-id></element-citation></ref><ref id="B54-cancers-11-01574"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawauchi</surname><given-names>K.</given-names></name><name><surname>Araki</surname><given-names>K.</given-names></name><name><surname>Tobiume</surname><given-names>K.</given-names></name><name><surname>Tanaka</surname><given-names>N.</given-names></name></person-group><article-title>p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation</article-title><source>Nat. Cell Biol.</source><year>2008</year><volume>10</volume><fpage>611</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1038/ncb1724</pub-id><?supplied-pmid 18391940?><pub-id pub-id-type="pmid">18391940</pub-id></element-citation></ref><ref id="B55-cancers-11-01574"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondoh</surname><given-names>H.</given-names></name><name><surname>Lleonart</surname><given-names>M.E.</given-names></name><name><surname>Gil</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Degan</surname><given-names>P.</given-names></name><name><surname>Peters</surname><given-names>G.</given-names></name><name><surname>Martinez</surname><given-names>D.</given-names></name><name><surname>Carnero</surname><given-names>A.</given-names></name><name><surname>Beach</surname><given-names>D.</given-names></name></person-group><article-title>Glycolytic enzymes can modulate cellular life span</article-title><source>Cancer Res.</source><year>2005</year><volume>65</volume><fpage>177</fpage><lpage>185</lpage><?supplied-pmid 15665293?><pub-id pub-id-type="pmid">15665293</pub-id></element-citation></ref><ref id="B56-cancers-11-01574"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathupala</surname><given-names>S.P.</given-names></name><name><surname>Heese</surname><given-names>C.</given-names></name><name><surname>Pedersen</surname><given-names>P.L.</given-names></name></person-group><article-title>Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53</article-title><source>J. Biol. Chem.</source><year>1997</year><volume>272</volume><fpage>22776</fpage><lpage>22780</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.36.22776</pub-id><?supplied-pmid 9278438?><pub-id pub-id-type="pmid">9278438</pub-id></element-citation></ref><ref id="B57-cancers-11-01574"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartzenberg-Bar-Yoseph</surname><given-names>F.</given-names></name><name><surname>Armoni</surname><given-names>M.</given-names></name><name><surname>Karnieli</surname><given-names>E.</given-names></name></person-group><article-title>The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression</article-title><source>Cancer Res.</source><year>2004</year><volume>64</volume><fpage>2627</fpage><lpage>2633</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-0846</pub-id><?supplied-pmid 15059920?><pub-id pub-id-type="pmid">15059920</pub-id></element-citation></ref><ref id="B58-cancers-11-01574"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boidot</surname><given-names>R.</given-names></name><name><surname>Vegran</surname><given-names>F.</given-names></name><name><surname>Meulle</surname><given-names>A.</given-names></name><name><surname>Le Breton</surname><given-names>A.</given-names></name><name><surname>Dessy</surname><given-names>C.</given-names></name><name><surname>Sonveaux</surname><given-names>P.</given-names></name><name><surname>Lizard-Nacol</surname><given-names>S.</given-names></name><name><surname>Feron</surname><given-names>O.</given-names></name></person-group><article-title>Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors</article-title><source>Cancer Res.</source><year>2012</year><volume>72</volume><fpage>939</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-2474</pub-id><?supplied-pmid 22184616?><pub-id pub-id-type="pmid">22184616</pub-id></element-citation></ref><ref id="B59-cancers-11-01574"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contractor</surname><given-names>T.</given-names></name><name><surname>Harris</surname><given-names>C.R.</given-names></name></person-group><article-title>p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2</article-title><source>Cancer Res.</source><year>2012</year><volume>72</volume><fpage>560</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1215</pub-id><pub-id pub-id-type="pmid">22123926</pub-id></element-citation></ref><ref id="B60-cancers-11-01574"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourdon</surname><given-names>A.</given-names></name><name><surname>Minai</surname><given-names>L.</given-names></name><name><surname>Serre</surname><given-names>V.</given-names></name><name><surname>Jais</surname><given-names>J.P.</given-names></name><name><surname>Sarzi</surname><given-names>E.</given-names></name><name><surname>Aubert</surname><given-names>S.</given-names></name><name><surname>Chretien</surname><given-names>D.</given-names></name><name><surname>de Lonlay</surname><given-names>P.</given-names></name><name><surname>Paquis-Flucklinger</surname><given-names>V.</given-names></name><name><surname>Arakawa</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion</article-title><source>Nat. Genet.</source><year>2007</year><volume>39</volume><fpage>776</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1038/ng2040</pub-id><pub-id pub-id-type="pmid">17486094</pub-id></element-citation></ref><ref id="B61-cancers-11-01574"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebedeva</surname><given-names>M.A.</given-names></name><name><surname>Eaton</surname><given-names>J.S.</given-names></name><name><surname>Shadel</surname><given-names>G.S.</given-names></name></person-group><article-title>Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis</article-title><source>Biochim. Biophys. Acta</source><year>2009</year><volume>1787</volume><fpage>328</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.bbabio.2009.01.004</pub-id><pub-id pub-id-type="pmid">19413947</pub-id></element-citation></ref><ref id="B62-cancers-11-01574"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matoba</surname><given-names>S.</given-names></name><name><surname>Kang</surname><given-names>J.G.</given-names></name><name><surname>Patino</surname><given-names>W.D.</given-names></name><name><surname>Wragg</surname><given-names>A.</given-names></name><name><surname>Boehm</surname><given-names>M.</given-names></name><name><surname>Gavrilova</surname><given-names>O.</given-names></name><name><surname>Hurley</surname><given-names>P.J.</given-names></name><name><surname>Bunz</surname><given-names>F.</given-names></name><name><surname>Hwang</surname><given-names>P.M.</given-names></name></person-group><article-title>p53 regulates mitochondrial respiration</article-title><source>Science</source><year>2006</year><volume>312</volume><fpage>1650</fpage><lpage>1653</lpage><pub-id pub-id-type="doi">10.1126/science.1126863</pub-id><pub-id pub-id-type="pmid">16728594</pub-id></element-citation></ref><ref id="B63-cancers-11-01574"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stambolsky</surname><given-names>P.</given-names></name><name><surname>Weisz</surname><given-names>L.</given-names></name><name><surname>Shats</surname><given-names>I.</given-names></name><name><surname>Klein</surname><given-names>Y.</given-names></name><name><surname>Goldfinger</surname><given-names>N.</given-names></name><name><surname>Oren</surname><given-names>M.</given-names></name><name><surname>Rotter</surname><given-names>V.</given-names></name></person-group><article-title>Regulation of AIF expression by p53</article-title><source>Cell Death Differ.</source><year>2006</year><volume>13</volume><fpage>2140</fpage><lpage>2149</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4401965</pub-id><?supplied-pmid 16729031?><pub-id pub-id-type="pmid">16729031</pub-id></element-citation></ref><ref id="B64-cancers-11-01574"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Floter</surname><given-names>J.</given-names></name><name><surname>Kaymak</surname><given-names>I.</given-names></name><name><surname>Schulze</surname><given-names>A.</given-names></name></person-group><article-title>Regulation of Metabolic Activity by p53</article-title><source>Metabolites</source><year>2017</year><volume>7</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.3390/metabo7020021</pub-id><?supplied-pmid 28531108?><pub-id pub-id-type="pmid">28531108</pub-id></element-citation></ref><ref id="B65-cancers-11-01574"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Hong</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>M.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Levine</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>Tumour-associated mutant p53 drives the Warburg effect</article-title><source>Nat. Commun.</source><year>2013</year><volume>4</volume><fpage>2935</fpage><pub-id pub-id-type="doi">10.1038/ncomms3935</pub-id><?supplied-pmid 24343302?><pub-id pub-id-type="pmid">24343302</pub-id></element-citation></ref><ref id="B66-cancers-11-01574"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Son</surname><given-names>J.</given-names></name><name><surname>Lyssiotis</surname><given-names>C.A.</given-names></name><name><surname>Ying</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Hua</surname><given-names>S.</given-names></name><name><surname>Ligorio</surname><given-names>M.</given-names></name><name><surname>Perera</surname><given-names>R.M.</given-names></name><name><surname>Ferrone</surname><given-names>C.R.</given-names></name><name><surname>Mullarky</surname><given-names>E.</given-names></name><name><surname>Shyh-Chang</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway</article-title><source>Nature</source><year>2013</year><volume>496</volume><fpage>101</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1038/nature12040</pub-id><pub-id pub-id-type="pmid">23535601</pub-id></element-citation></ref><ref id="B67-cancers-11-01574"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuneva</surname><given-names>M.O.</given-names></name><name><surname>Fan</surname><given-names>T.W.</given-names></name><name><surname>Allen</surname><given-names>T.D.</given-names></name><name><surname>Higashi</surname><given-names>R.M.</given-names></name><name><surname>Ferraris</surname><given-names>D.V.</given-names></name><name><surname>Tsukamoto</surname><given-names>T.</given-names></name><name><surname>Mates</surname><given-names>J.M.</given-names></name><name><surname>Alonso</surname><given-names>F.J.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Seo</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type</article-title><source>Cell Metab.</source><year>2012</year><volume>15</volume><fpage>157</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2011.12.015</pub-id><pub-id pub-id-type="pmid">22326218</pub-id></element-citation></ref><ref id="B68-cancers-11-01574"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarkson</surname><given-names>B.</given-names></name><name><surname>Fried</surname><given-names>J.</given-names></name><name><surname>Strife</surname><given-names>A.</given-names></name><name><surname>Sakai</surname><given-names>Y.</given-names></name><name><surname>Ota</surname><given-names>K.</given-names></name><name><surname>Okita</surname><given-names>T.</given-names></name></person-group><article-title>Studies of cellular proliferation in human leukemia. 3. Behavior of leukemic cells in three adults with acute leukemia given continuous infusions of 3H-thymidine for 8 or 10 days</article-title><source>Cancer</source><year>1970</year><volume>25</volume><fpage>1237</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(197006)25:6&#x0003c;1237::AID-CNCR2820250602&#x0003e;3.0.CO;2-7</pub-id><pub-id pub-id-type="pmid">4246416</pub-id></element-citation></ref><ref id="B69-cancers-11-01574"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarkson</surname><given-names>B.D.</given-names></name></person-group><article-title>Review of recent studies of cellular proliferation in acute leukemia</article-title><source>Natl. Cancer Inst. Monogr.</source><year>1969</year><volume>30</volume><fpage>81</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">5260445</pub-id></element-citation></ref><ref id="B70-cancers-11-01574"><label>70.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Viale</surname><given-names>A.</given-names></name><name><surname>Pelicci</surname><given-names>P.</given-names></name></person-group><source>Regulation of Self-Renewing Division in Normal and Leukaemia Stem Cells</source><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2010</year></element-citation></ref><ref id="B71-cancers-11-01574"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carette</surname><given-names>J.E.</given-names></name><name><surname>Pruszak</surname><given-names>J.</given-names></name><name><surname>Varadarajan</surname><given-names>M.</given-names></name><name><surname>Blomen</surname><given-names>V.A.</given-names></name><name><surname>Gokhale</surname><given-names>S.</given-names></name><name><surname>Camargo</surname><given-names>F.D.</given-names></name><name><surname>Wernig</surname><given-names>M.</given-names></name><name><surname>Jaenisch</surname><given-names>R.</given-names></name><name><surname>Brummelkamp</surname><given-names>T.R.</given-names></name></person-group><article-title>Generation of iPSCs from cultured human malignant cells</article-title><source>Blood</source><year>2010</year><volume>115</volume><fpage>4039</fpage><lpage>4042</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-07-231845</pub-id><pub-id pub-id-type="pmid">20233975</pub-id></element-citation></ref><ref id="B72-cancers-11-01574"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochedlinger</surname><given-names>K.</given-names></name><name><surname>Blelloch</surname><given-names>R.</given-names></name><name><surname>Brennan</surname><given-names>C.</given-names></name><name><surname>Yamada</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Chin</surname><given-names>L.</given-names></name><name><surname>Jaenisch</surname><given-names>R.</given-names></name></person-group><article-title>Reprogramming of a melanoma genome by nuclear transplantation</article-title><source>Genes Dev.</source><year>2004</year><volume>18</volume><fpage>1875</fpage><lpage>1885</lpage><pub-id pub-id-type="doi">10.1101/gad.1213504</pub-id><pub-id pub-id-type="pmid">15289459</pub-id></element-citation></ref><ref id="B73-cancers-11-01574"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mintz</surname><given-names>B.</given-names></name><name><surname>Illmensee</surname><given-names>K.</given-names></name></person-group><article-title>Normal genetically mosaic mice produced from malignant teratocarcinoma cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1975</year><volume>72</volume><fpage>3585</fpage><lpage>3589</lpage><pub-id pub-id-type="doi">10.1073/pnas.72.9.3585</pub-id><pub-id pub-id-type="pmid">1059147</pub-id></element-citation></ref><ref id="B74-cancers-11-01574"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genovese</surname><given-names>G.</given-names></name><name><surname>Carugo</surname><given-names>A.</given-names></name><name><surname>Tepper</surname><given-names>J.</given-names></name><name><surname>Robinson</surname><given-names>F.S.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Svelto</surname><given-names>M.</given-names></name><name><surname>Nezi</surname><given-names>L.</given-names></name><name><surname>Corti</surname><given-names>D.</given-names></name><name><surname>Minelli</surname><given-names>R.</given-names></name><name><surname>Pettazzoni</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer</article-title><source>Nature</source><year>2017</year><volume>542</volume><fpage>362</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1038/nature21064</pub-id><?supplied-pmid 28178232?><pub-id pub-id-type="pmid">28178232</pub-id></element-citation></ref><ref id="B75-cancers-11-01574"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lissanu Deribe</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Terranova</surname><given-names>C.</given-names></name><name><surname>Khan</surname><given-names>F.</given-names></name><name><surname>Martinez-Ledesma</surname><given-names>J.</given-names></name><name><surname>Gay</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>G.</given-names></name><name><surname>Mullinax</surname><given-names>R.A.</given-names></name><name><surname>Khor</surname><given-names>T.</given-names></name><name><surname>Feng</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer</article-title><source>Nat. Med.</source><year>2018</year><volume>24</volume><fpage>1047</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0019-5</pub-id><?supplied-pmid 29892061?><pub-id pub-id-type="pmid">29892061</pub-id></element-citation></ref><ref id="B76-cancers-11-01574"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roesch</surname><given-names>A.</given-names></name><name><surname>Fukunaga-Kalabis</surname><given-names>M.</given-names></name><name><surname>Schmidt</surname><given-names>E.C.</given-names></name><name><surname>Zabierowski</surname><given-names>S.E.</given-names></name><name><surname>Brafford</surname><given-names>P.A.</given-names></name><name><surname>Vultur</surname><given-names>A.</given-names></name><name><surname>Basu</surname><given-names>D.</given-names></name><name><surname>Gimotty</surname><given-names>P.</given-names></name><name><surname>Vogt</surname><given-names>T.</given-names></name><name><surname>Herlyn</surname><given-names>M.</given-names></name></person-group><article-title>A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth</article-title><source>Cell</source><year>2010</year><volume>141</volume><fpage>583</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.04.020</pub-id><?supplied-pmid 20478252?><pub-id pub-id-type="pmid">20478252</pub-id></element-citation></ref><ref id="B77-cancers-11-01574"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roesch</surname><given-names>A.</given-names></name><name><surname>Vultur</surname><given-names>A.</given-names></name><name><surname>Bogeski</surname><given-names>I.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Zimmermann</surname><given-names>K.M.</given-names></name><name><surname>Speicher</surname><given-names>D.</given-names></name><name><surname>Korbel</surname><given-names>C.</given-names></name><name><surname>Laschke</surname><given-names>M.W.</given-names></name><name><surname>Gimotty</surname><given-names>P.A.</given-names></name><name><surname>Philipp</surname><given-names>S.E.</given-names></name><etal/></person-group><article-title>Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells</article-title><source>Cancer cell</source><year>2013</year><volume>23</volume><fpage>811</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.05.003</pub-id><?supplied-pmid 23764003?><pub-id pub-id-type="pmid">23764003</pub-id></element-citation></ref><ref id="B78-cancers-11-01574"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viale</surname><given-names>A.</given-names></name><name><surname>Draetta</surname><given-names>G.F.</given-names></name></person-group><article-title>Metabolic Features of Cancer Treatment Resistance</article-title><source>Recent Results Cancer Res.</source><year>2016</year><volume>207</volume><fpage>135</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-42118-6_6</pub-id><pub-id pub-id-type="pmid">27557537</pub-id></element-citation></ref><ref id="B79-cancers-11-01574"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viale</surname><given-names>A.</given-names></name><name><surname>Pettazzoni</surname><given-names>P.</given-names></name><name><surname>Lyssiotis</surname><given-names>C.A.</given-names></name><name><surname>Ying</surname><given-names>H.</given-names></name><name><surname>Sanchez</surname><given-names>N.</given-names></name><name><surname>Marchesini</surname><given-names>M.</given-names></name><name><surname>Carugo</surname><given-names>A.</given-names></name><name><surname>Green</surname><given-names>T.</given-names></name><name><surname>Seth</surname><given-names>S.</given-names></name><name><surname>Giuliani</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function</article-title><source>Nature</source><year>2014</year><volume>514</volume><fpage>628</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1038/nature13611</pub-id><pub-id pub-id-type="pmid">25119024</pub-id></element-citation></ref><ref id="B80-cancers-11-01574"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilmore</surname><given-names>I.S.</given-names></name><name><surname>Heiles</surname><given-names>S.</given-names></name><name><surname>Pieterse</surname><given-names>C.L.</given-names></name></person-group><article-title>Metabolic Imaging at the Single-Cell Scale: Recent Advances in Mass Spectrometry Imaging</article-title><source>Annu. Rev. Anal. Chem. (Palo Alto Calif.)</source><year>2019</year><volume>12</volume><fpage>201</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1146/annurev-anchem-061318-115516</pub-id><pub-id pub-id-type="pmid">30848927</pub-id></element-citation></ref><ref id="B81-cancers-11-01574"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Connor</surname><given-names>J.P.</given-names></name><name><surname>Rose</surname><given-names>C.J.</given-names></name><name><surname>Waterton</surname><given-names>J.C.</given-names></name><name><surname>Carano</surname><given-names>R.A.</given-names></name><name><surname>Parker</surname><given-names>G.J.</given-names></name><name><surname>Jackson</surname><given-names>A.</given-names></name></person-group><article-title>Imaging intratumor heterogeneity: Role in therapy response, resistance, and clinical outcome</article-title><source>Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</source><year>2015</year><volume>21</volume><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0990</pub-id></element-citation></ref><ref id="B82-cancers-11-01574"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillies</surname><given-names>R.J.</given-names></name><name><surname>Kinahan</surname><given-names>P.E.</given-names></name><name><surname>Hricak</surname><given-names>H.</given-names></name></person-group><article-title>Radiomics: Images Are More than Pictures, They Are Data</article-title><source>Radiology</source><year>2016</year><volume>278</volume><fpage>563</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1148/radiol.2015151169</pub-id><pub-id pub-id-type="pmid">26579733</pub-id></element-citation></ref><ref id="B83-cancers-11-01574"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aerts</surname><given-names>H.J.</given-names></name><name><surname>Velazquez</surname><given-names>E.R.</given-names></name><name><surname>Leijenaar</surname><given-names>R.T.</given-names></name><name><surname>Parmar</surname><given-names>C.</given-names></name><name><surname>Grossmann</surname><given-names>P.</given-names></name><name><surname>Carvalho</surname><given-names>S.</given-names></name><name><surname>Bussink</surname><given-names>J.</given-names></name><name><surname>Monshouwer</surname><given-names>R.</given-names></name><name><surname>Haibe-Kains</surname><given-names>B.</given-names></name><name><surname>Rietveld</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>4006</fpage><pub-id pub-id-type="doi">10.1038/ncomms5006</pub-id><pub-id pub-id-type="pmid">24892406</pub-id></element-citation></ref><ref id="B84-cancers-11-01574"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurhanewicz</surname><given-names>J.</given-names></name><name><surname>Vigneron</surname><given-names>D.B.</given-names></name><name><surname>Ardenkjaer-Larsen</surname><given-names>J.H.</given-names></name><name><surname>Bankson</surname><given-names>J.A.</given-names></name><name><surname>Brindle</surname><given-names>K.</given-names></name><name><surname>Cunningham</surname><given-names>C.H.</given-names></name><name><surname>Gallagher</surname><given-names>F.A.</given-names></name><name><surname>Keshari</surname><given-names>K.R.</given-names></name><name><surname>Kjaer</surname><given-names>A.</given-names></name><name><surname>Laustsen</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Hyperpolarized (13)C MRI: Path to Clinical Translation in Oncology</article-title><source>Neoplasia</source><year>2019</year><volume>21</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2018.09.006</pub-id><?supplied-pmid 30472500?><pub-id pub-id-type="pmid">30472500</pub-id></element-citation></ref><ref id="B85-cancers-11-01574"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>P.</given-names></name><name><surname>Salzillo</surname><given-names>T.C.</given-names></name><name><surname>Pudakalakatti</surname><given-names>S.</given-names></name><name><surname>Gammon</surname><given-names>S.T.</given-names></name><name><surname>Kaipparettu</surname><given-names>B.A.</given-names></name><name><surname>McAllister</surname><given-names>F.</given-names></name><name><surname>Wagner</surname><given-names>S.</given-names></name><name><surname>Frigo</surname><given-names>D.E.</given-names></name><name><surname>Logothetis</surname><given-names>C.J.</given-names></name><name><surname>Zacharias</surname><given-names>N.M.</given-names></name><etal/></person-group><article-title>Assessing Therapeutic Efficacy in Real-time by Hyperpolarized Magnetic Resonance Metabolic Imaging</article-title><source>Cells</source><year>2019</year><volume>8</volume><elocation-id>340</elocation-id><pub-id pub-id-type="doi">10.3390/cells8040340</pub-id><?supplied-pmid 30978984?><pub-id pub-id-type="pmid">30978984</pub-id></element-citation></ref><ref id="B86-cancers-11-01574"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fathi Kazerooni</surname><given-names>A.</given-names></name><name><surname>Bakas</surname><given-names>S.</given-names></name><name><surname>Saligheh Rad</surname><given-names>H.</given-names></name><name><surname>Davatzikos</surname><given-names>C.</given-names></name></person-group><article-title>Imaging signatures of glioblastoma molecular characteristics: A radiogenomics review</article-title><source>J. Magn. Reson. Imaging</source><year>2019</year><pub-id pub-id-type="doi">10.1002/jmri.26907</pub-id></element-citation></ref><ref id="B87-cancers-11-01574"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>W.K.</given-names></name><name><surname>Jamshidi</surname><given-names>N.</given-names></name><name><surname>Felker</surname><given-names>E.R.</given-names></name><name><surname>Raman</surname><given-names>S.S.</given-names></name><name><surname>Lu</surname><given-names>D.S.</given-names></name></person-group><article-title>Radiomics and radiogenomics of primary liver cancers</article-title><source>Clin. Mol. Hepatol.</source><year>2019</year><volume>25</volume><fpage>21</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.3350/cmh.2018.1007</pub-id><?supplied-pmid 30441889?><pub-id pub-id-type="pmid">30441889</pub-id></element-citation></ref><ref id="B88-cancers-11-01574"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reig</surname><given-names>B.</given-names></name><name><surname>Heacock</surname><given-names>L.</given-names></name><name><surname>Geras</surname><given-names>K.J.</given-names></name><name><surname>Moy</surname><given-names>L.</given-names></name></person-group><article-title>Machine learning in breast MRI</article-title><source>J. Magn. Reson. Imaging</source><year>2019</year><pub-id pub-id-type="doi">10.1002/jmri.26852</pub-id><?supplied-pmid 31276247?><pub-id pub-id-type="pmid">31276247</pub-id></element-citation></ref><ref id="B89-cancers-11-01574"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maher</surname><given-names>E.A.</given-names></name><name><surname>Marin-Valencia</surname><given-names>I.</given-names></name><name><surname>Bachoo</surname><given-names>R.M.</given-names></name><name><surname>Mashimo</surname><given-names>T.</given-names></name><name><surname>Raisanen</surname><given-names>J.</given-names></name><name><surname>Hatanpaa</surname><given-names>K.J.</given-names></name><name><surname>Jindal</surname><given-names>A.</given-names></name><name><surname>Jeffrey</surname><given-names>F.M.</given-names></name><name><surname>Choi</surname><given-names>C.</given-names></name><name><surname>Madden</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Metabolism of [U-13 C]glucose in human brain tumors in vivo</article-title><source>NMR Biomed.</source><year>2012</year><volume>25</volume><fpage>1234</fpage><lpage>1244</lpage><pub-id pub-id-type="doi">10.1002/nbm.2794</pub-id><pub-id pub-id-type="pmid">22419606</pub-id></element-citation></ref><ref id="B90-cancers-11-01574"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marin-Valencia</surname><given-names>I.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Mashimo</surname><given-names>T.</given-names></name><name><surname>Cho</surname><given-names>S.</given-names></name><name><surname>Baek</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>X.L.</given-names></name><name><surname>Rajagopalan</surname><given-names>K.N.</given-names></name><name><surname>Maddie</surname><given-names>M.</given-names></name><name><surname>Vemireddy</surname><given-names>V.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo</article-title><source>Cell Metab.</source><year>2012</year><volume>15</volume><fpage>827</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2012.05.001</pub-id><pub-id pub-id-type="pmid">22682223</pub-id></element-citation></ref><ref id="B91-cancers-11-01574"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sellers</surname><given-names>K.</given-names></name><name><surname>Fox</surname><given-names>M.P.</given-names></name><name><surname>Bousamra</surname><given-names>M.</given-names><suffix>II</suffix></name><name><surname>Slone</surname><given-names>S.P.</given-names></name><name><surname>Higashi</surname><given-names>R.M.</given-names></name><name><surname>Miller</surname><given-names>D.M.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Yan</surname><given-names>J.</given-names></name><name><surname>Yuneva</surname><given-names>M.O.</given-names></name><name><surname>Deshpande</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation</article-title><source>J. Clin. Investig.</source><year>2015</year><volume>125</volume><fpage>687</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1172/JCI72873</pub-id><pub-id pub-id-type="pmid">25607840</pub-id></element-citation></ref><ref id="B92-cancers-11-01574"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hensley</surname><given-names>C.T.</given-names></name><name><surname>Faubert</surname><given-names>B.</given-names></name><name><surname>Yuan</surname><given-names>Q.</given-names></name><name><surname>Lev-Cohain</surname><given-names>N.</given-names></name><name><surname>Jin</surname><given-names>E.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Ko</surname><given-names>B.</given-names></name><name><surname>Skelton</surname><given-names>R.</given-names></name><name><surname>Loudat</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Metabolic Heterogeneity in Human Lung Tumors</article-title><source>Cell</source><year>2016</year><volume>164</volume><fpage>681</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.12.034</pub-id><pub-id pub-id-type="pmid">26853473</pub-id></element-citation></ref><ref id="B93-cancers-11-01574"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faubert</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>K.Y.</given-names></name><name><surname>Cai</surname><given-names>L.</given-names></name><name><surname>Hensley</surname><given-names>C.T.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Zacharias</surname><given-names>L.G.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Do</surname><given-names>Q.N.</given-names></name><name><surname>Doucette</surname><given-names>S.</given-names></name><name><surname>Burguete</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Lactate Metabolism in Human Lung Tumors</article-title><source>Cell</source><year>2017</year><volume>171</volume><fpage>358</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.09.019</pub-id><pub-id pub-id-type="pmid">28985563</pub-id></element-citation></ref><ref id="B94-cancers-11-01574"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hensley</surname><given-names>C.T.</given-names></name><name><surname>DeBerardinis</surname><given-names>R.J.</given-names></name></person-group><article-title>In vivo analysis of lung cancer metabolism: Nothing like the real thing</article-title><source>J. Clin. Investig.</source><year>2015</year><volume>125</volume><fpage>495</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1172/JCI79188</pub-id><?supplied-pmid 25607834?><pub-id pub-id-type="pmid">25607834</pub-id></element-citation></ref><ref id="B95-cancers-11-01574"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyssiotis</surname><given-names>C.A.</given-names></name><name><surname>Kimmelman</surname><given-names>A.C.</given-names></name></person-group><article-title>Metabolic Interactions in the Tumor Microenvironment</article-title><source>Trends Cell Biol.</source><year>2017</year><volume>27</volume><fpage>863</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2017.06.003</pub-id><?supplied-pmid 28734735?><pub-id pub-id-type="pmid">28734735</pub-id></element-citation></ref><ref id="B96-cancers-11-01574"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalluri</surname><given-names>R.</given-names></name></person-group><article-title>The biology and function of fibroblasts in cancer</article-title><source>Nat. Rev. Cancer</source><year>2016</year><volume>16</volume><fpage>582</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.73</pub-id><?supplied-pmid 27550820?><pub-id pub-id-type="pmid">27550820</pub-id></element-citation></ref><ref id="B97-cancers-11-01574"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiaschi</surname><given-names>T.</given-names></name><name><surname>Marini</surname><given-names>A.</given-names></name><name><surname>Giannoni</surname><given-names>E.</given-names></name><name><surname>Taddei</surname><given-names>M.L.</given-names></name><name><surname>Gandellini</surname><given-names>P.</given-names></name><name><surname>De Donatis</surname><given-names>A.</given-names></name><name><surname>Lanciotti</surname><given-names>M.</given-names></name><name><surname>Serni</surname><given-names>S.</given-names></name><name><surname>Cirri</surname><given-names>P.</given-names></name><name><surname>Chiarugi</surname><given-names>P.</given-names></name></person-group><article-title>Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay</article-title><source>Cancer Res.</source><year>2012</year><volume>72</volume><fpage>5130</fpage><lpage>5140</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-1949</pub-id><pub-id pub-id-type="pmid">22850421</pub-id></element-citation></ref><ref id="B98-cancers-11-01574"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Baddour</surname><given-names>J.</given-names></name><name><surname>Achreja</surname><given-names>A.</given-names></name><name><surname>Bernard</surname><given-names>V.</given-names></name><name><surname>Moss</surname><given-names>T.</given-names></name><name><surname>Marini</surname><given-names>J.C.</given-names></name><name><surname>Tudawe</surname><given-names>T.</given-names></name><name><surname>Seviour</surname><given-names>E.G.</given-names></name><name><surname>San Lucas</surname><given-names>F.A.</given-names></name><etal/></person-group><article-title>Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism</article-title><source>Elife</source><year>2016</year><volume>5</volume><fpage>e10250</fpage><pub-id pub-id-type="doi">10.7554/eLife.10250</pub-id><pub-id pub-id-type="pmid">26920219</pub-id></element-citation></ref><ref id="B99-cancers-11-01574"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Achreja</surname><given-names>A.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Yun</surname><given-names>T.H.</given-names></name><name><surname>Marini</surname><given-names>J.</given-names></name><name><surname>Nagrath</surname><given-names>D.</given-names></name></person-group><article-title>Exo-MFA&#x02014;A 13C metabolic flux analysis framework to dissect tumor microenvironment-secreted exosome contributions towards cancer cell metabolism</article-title><source>Metab. Eng.</source><year>2017</year><volume>43</volume><fpage>156</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.ymben.2017.01.001</pub-id><pub-id pub-id-type="pmid">28087332</pub-id></element-citation></ref><ref id="B100-cancers-11-01574"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Fong</surname><given-names>M.Y.</given-names></name><name><surname>Cao</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>C.H.</given-names></name><name><surname>Fadare</surname><given-names>O.</given-names></name><name><surname>Pizzo</surname><given-names>D.P.</given-names></name><etal/></person-group><article-title>Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells</article-title><source>Nat. Cell Biol.</source><year>2018</year><volume>20</volume><fpage>597</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1038/s41556-018-0083-6</pub-id><pub-id pub-id-type="pmid">29662176</pub-id></element-citation></ref><ref id="B101-cancers-11-01574"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlides</surname><given-names>S.</given-names></name><name><surname>Whitaker-Menezes</surname><given-names>D.</given-names></name><name><surname>Castello-Cros</surname><given-names>R.</given-names></name><name><surname>Flomenberg</surname><given-names>N.</given-names></name><name><surname>Witkiewicz</surname><given-names>A.K.</given-names></name><name><surname>Frank</surname><given-names>P.G.</given-names></name><name><surname>Casimiro</surname><given-names>M.C.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Fortina</surname><given-names>P.</given-names></name><name><surname>Addya</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma</article-title><source>Cell Cycle</source><year>2009</year><volume>8</volume><fpage>3984</fpage><lpage>4001</lpage><pub-id pub-id-type="doi">10.4161/cc.8.23.10238</pub-id><pub-id pub-id-type="pmid">19923890</pub-id></element-citation></ref><ref id="B102-cancers-11-01574"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlides</surname><given-names>S.</given-names></name><name><surname>Vera</surname><given-names>I.</given-names></name><name><surname>Gandara</surname><given-names>R.</given-names></name><name><surname>Sneddon</surname><given-names>S.</given-names></name><name><surname>Pestell</surname><given-names>R.G.</given-names></name><name><surname>Mercier</surname><given-names>I.</given-names></name><name><surname>Martinez-Outschoorn</surname><given-names>U.E.</given-names></name><name><surname>Whitaker-Menezes</surname><given-names>D.</given-names></name><name><surname>Howell</surname><given-names>A.</given-names></name><name><surname>Sotgia</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Warburg meets autophagy: Cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis</article-title><source>Antioxid. Redox Signal.</source><year>2012</year><volume>16</volume><fpage>1264</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1089/ars.2011.4243</pub-id><pub-id pub-id-type="pmid">21883043</pub-id></element-citation></ref><ref id="B103-cancers-11-01574"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Outschoorn</surname><given-names>U.E.</given-names></name><name><surname>Lisanti</surname><given-names>M.P.</given-names></name><name><surname>Sotgia</surname><given-names>F.</given-names></name></person-group><article-title>Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth</article-title><source>Semin. Cancer Biol.</source><year>2014</year><volume>25</volume><fpage>47</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2014.01.005</pub-id><?supplied-pmid 24486645?><pub-id pub-id-type="pmid">24486645</pub-id></element-citation></ref><ref id="B104-cancers-11-01574"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>P.</given-names></name><name><surname>Hou</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>B.P.</given-names></name><name><surname>Mi</surname><given-names>J.</given-names></name></person-group><article-title>Metabolic reprogramming of cancer-associated fibroblasts by IDH3alpha downregulation</article-title><source>Cell Rep.</source><year>2015</year><volume>10</volume><fpage>1335</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.02.006</pub-id><?supplied-pmid 25732824?><pub-id pub-id-type="pmid">25732824</pub-id></element-citation></ref><ref id="B105-cancers-11-01574"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonuccelli</surname><given-names>G.</given-names></name><name><surname>Tsirigos</surname><given-names>A.</given-names></name><name><surname>Whitaker-Menezes</surname><given-names>D.</given-names></name><name><surname>Pavlides</surname><given-names>S.</given-names></name><name><surname>Pestell</surname><given-names>R.G.</given-names></name><name><surname>Chiavarina</surname><given-names>B.</given-names></name><name><surname>Frank</surname><given-names>P.G.</given-names></name><name><surname>Flomenberg</surname><given-names>N.</given-names></name><name><surname>Howell</surname><given-names>A.</given-names></name><name><surname>Martinez-Outschoorn</surname><given-names>U.E.</given-names></name><etal/></person-group><article-title>Ketones and lactate &#x0201c;fuel&#x0201d; tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism</article-title><source>Cell Cycle</source><year>2010</year><volume>9</volume><fpage>3506</fpage><lpage>3514</lpage><pub-id pub-id-type="doi">10.4161/cc.9.17.12731</pub-id><?supplied-pmid 20818174?><pub-id pub-id-type="pmid">20818174</pub-id></element-citation></ref><ref id="B106-cancers-11-01574"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Outschoorn</surname><given-names>U.E.</given-names></name><name><surname>Lin</surname><given-names>Z.</given-names></name><name><surname>Whitaker-Menezes</surname><given-names>D.</given-names></name><name><surname>Howell</surname><given-names>A.</given-names></name><name><surname>Lisanti</surname><given-names>M.P.</given-names></name><name><surname>Sotgia</surname><given-names>F.</given-names></name></person-group><article-title>Ketone bodies and two-compartment tumor metabolism: Stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells</article-title><source>Cell Cycle</source><year>2012</year><volume>11</volume><fpage>3956</fpage><lpage>3963</lpage><pub-id pub-id-type="doi">10.4161/cc.22136</pub-id><?supplied-pmid 23082721?><pub-id pub-id-type="pmid">23082721</pub-id></element-citation></ref><ref id="B107-cancers-11-01574"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Outschoorn</surname><given-names>U.E.</given-names></name><name><surname>Lin</surname><given-names>Z.</given-names></name><name><surname>Whitaker-Menezes</surname><given-names>D.</given-names></name><name><surname>Howell</surname><given-names>A.</given-names></name><name><surname>Sotgia</surname><given-names>F.</given-names></name><name><surname>Lisanti</surname><given-names>M.P.</given-names></name></person-group><article-title>Ketone body utilization drives tumor growth and metastasis</article-title><source>Cell Cycle</source><year>2012</year><volume>11</volume><fpage>3964</fpage><lpage>3971</lpage><pub-id pub-id-type="doi">10.4161/cc.22137</pub-id><?supplied-pmid 23082722?><pub-id pub-id-type="pmid">23082722</pub-id></element-citation></ref><ref id="B108-cancers-11-01574"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sousa</surname><given-names>C.M.</given-names></name><name><surname>Biancur</surname><given-names>D.E.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Halbrook</surname><given-names>C.J.</given-names></name><name><surname>Sherman</surname><given-names>M.H.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Kremer</surname><given-names>D.</given-names></name><name><surname>Hwang</surname><given-names>R.F.</given-names></name><name><surname>Witkiewicz</surname><given-names>A.K.</given-names></name><name><surname>Ying</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion</article-title><source>Nature</source><year>2016</year><volume>536</volume><fpage>479</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1038/nature19084</pub-id><?supplied-pmid 27509858?><pub-id pub-id-type="pmid">27509858</pub-id></element-citation></ref><ref id="B109-cancers-11-01574"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Achreja</surname><given-names>A.</given-names></name><name><surname>Yeung</surname><given-names>T.L.</given-names></name><name><surname>Mangala</surname><given-names>L.S.</given-names></name><name><surname>Jiang</surname><given-names>D.</given-names></name><name><surname>Han</surname><given-names>C.</given-names></name><name><surname>Baddour</surname><given-names>J.</given-names></name><name><surname>Marini</surname><given-names>J.C.</given-names></name><name><surname>Ni</surname><given-names>J.</given-names></name><name><surname>Nakahara</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth</article-title><source>Cell Metab.</source><year>2016</year><volume>24</volume><fpage>685</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.10.011</pub-id><pub-id pub-id-type="pmid">27829138</pub-id></element-citation></ref><ref id="B110-cancers-11-01574"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tardito</surname><given-names>S.</given-names></name><name><surname>Oudin</surname><given-names>A.</given-names></name><name><surname>Ahmed</surname><given-names>S.U.</given-names></name><name><surname>Fack</surname><given-names>F.</given-names></name><name><surname>Keunen</surname><given-names>O.</given-names></name><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Miletic</surname><given-names>H.</given-names></name><name><surname>Sakariassen</surname><given-names>P.O.</given-names></name><name><surname>Weinstock</surname><given-names>A.</given-names></name><name><surname>Wagner</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma</article-title><source>Nat. Cell Biol.</source><year>2015</year><volume>17</volume><fpage>1556</fpage><lpage>1568</lpage><pub-id pub-id-type="doi">10.1038/ncb3272</pub-id><pub-id pub-id-type="pmid">26595383</pub-id></element-citation></ref><ref id="B111-cancers-11-01574"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>K.A.</given-names></name><name><surname>Neeley</surname><given-names>C.K.</given-names></name><name><surname>Baker</surname><given-names>N.A.</given-names></name><name><surname>Washabaugh</surname><given-names>A.R.</given-names></name><name><surname>Flesher</surname><given-names>C.G.</given-names></name><name><surname>Nelson</surname><given-names>B.S.</given-names></name><name><surname>Frankel</surname><given-names>T.L.</given-names></name><name><surname>Lumeng</surname><given-names>C.N.</given-names></name><name><surname>Lyssiotis</surname><given-names>C.A.</given-names></name><name><surname>Wynn</surname><given-names>M.L.</given-names></name><etal/></person-group><article-title>Adipocytes promote pancreatic cancer cell proliferation via glutamine transfer</article-title><source>Biochem. Biophys. Rep.</source><year>2016</year><volume>7</volume><fpage>144</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.bbrep.2016.06.004</pub-id><pub-id pub-id-type="pmid">27617308</pub-id></element-citation></ref><ref id="B112-cancers-11-01574"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Trachootham</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Pelicano</surname><given-names>H.</given-names></name><name><surname>Garcia-Prieto</surname><given-names>C.</given-names></name><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>Burger</surname><given-names>J.A.</given-names></name><name><surname>Croce</surname><given-names>C.M.</given-names></name><name><surname>Plunkett</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia</article-title><source>Nat. Cell Biol.</source><year>2012</year><volume>14</volume><fpage>276</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1038/ncb2432</pub-id><pub-id pub-id-type="pmid">22344033</pub-id></element-citation></ref><ref id="B113-cancers-11-01574"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Kryczek</surname><given-names>I.</given-names></name><name><surname>Dostal</surname><given-names>L.</given-names></name><name><surname>Lin</surname><given-names>H.</given-names></name><name><surname>Tan</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>F.</given-names></name><name><surname>Wei</surname><given-names>S.</given-names></name><name><surname>Maj</surname><given-names>T.</given-names></name><name><surname>Peng</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer</article-title><source>Cell</source><year>2016</year><volume>165</volume><fpage>1092</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.04.009</pub-id><pub-id pub-id-type="pmid">27133165</pub-id></element-citation></ref><ref id="B114-cancers-11-01574"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallarino</surname><given-names>F.</given-names></name><name><surname>Grohmann</surname><given-names>U.</given-names></name><name><surname>Vacca</surname><given-names>C.</given-names></name><name><surname>Bianchi</surname><given-names>R.</given-names></name><name><surname>Orabona</surname><given-names>C.</given-names></name><name><surname>Spreca</surname><given-names>A.</given-names></name><name><surname>Fioretti</surname><given-names>M.C.</given-names></name><name><surname>Puccetti</surname><given-names>P.</given-names></name></person-group><article-title>T cell apoptosis by tryptophan catabolism</article-title><source>Cell Death Differ.</source><year>2002</year><volume>9</volume><fpage>1069</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4401073</pub-id><pub-id pub-id-type="pmid">12232795</pub-id></element-citation></ref><ref id="B115-cancers-11-01574"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platten</surname><given-names>M.</given-names></name><name><surname>Wick</surname><given-names>W.</given-names></name><name><surname>Van den Eynde</surname><given-names>B.J.</given-names></name></person-group><article-title>Tryptophan catabolism in cancer: Beyond IDO and tryptophan depletion</article-title><source>Cancer Res.</source><year>2012</year><volume>72</volume><fpage>5435</fpage><lpage>5440</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-0569</pub-id><?supplied-pmid 23090118?><pub-id pub-id-type="pmid">23090118</pub-id></element-citation></ref><ref id="B116-cancers-11-01574"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>N.T.</given-names></name><name><surname>Kimura</surname><given-names>A.</given-names></name><name><surname>Nakahama</surname><given-names>T.</given-names></name><name><surname>Chinen</surname><given-names>I.</given-names></name><name><surname>Masuda</surname><given-names>K.</given-names></name><name><surname>Nohara</surname><given-names>K.</given-names></name><name><surname>Fujii-Kuriyama</surname><given-names>Y.</given-names></name><name><surname>Kishimoto</surname><given-names>T.</given-names></name></person-group><article-title>Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>19961</fpage><lpage>19966</lpage><pub-id pub-id-type="doi">10.1073/pnas.1014465107</pub-id><?supplied-pmid 21041655?><pub-id pub-id-type="pmid">21041655</pub-id></element-citation></ref><ref id="B117-cancers-11-01574"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timosenko</surname><given-names>E.</given-names></name><name><surname>Hadjinicolaou</surname><given-names>A.V.</given-names></name><name><surname>Cerundolo</surname><given-names>V.</given-names></name></person-group><article-title>Modulation of cancer-specific immune responses by amino acid degrading enzymes</article-title><source>Immunotherapy</source><year>2017</year><volume>9</volume><fpage>83</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.2217/imt-2016-0118</pub-id><?supplied-pmid 28000524?><pub-id pub-id-type="pmid">28000524</pub-id></element-citation></ref><ref id="B118-cancers-11-01574"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>M.</given-names></name><name><surname>Ramirez</surname><given-names>M.E.</given-names></name><name><surname>Sierra</surname><given-names>R.A.</given-names></name><name><surname>Raber</surname><given-names>P.</given-names></name><name><surname>Thevenot</surname><given-names>P.</given-names></name><name><surname>Al-Khami</surname><given-names>A.A.</given-names></name><name><surname>Sanchez-Pino</surname><given-names>D.</given-names></name><name><surname>Hernandez</surname><given-names>C.</given-names></name><name><surname>Wyczechowska</surname><given-names>D.D.</given-names></name><name><surname>Ochoa</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells</article-title><source>Cancer Res.</source><year>2015</year><volume>75</volume><fpage>275</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-1491</pub-id><pub-id pub-id-type="pmid">25406192</pub-id></element-citation></ref><ref id="B119-cancers-11-01574"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geiger</surname><given-names>R.</given-names></name><name><surname>Rieckmann</surname><given-names>J.C.</given-names></name><name><surname>Wolf</surname><given-names>T.</given-names></name><name><surname>Basso</surname><given-names>C.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Fuhrer</surname><given-names>T.</given-names></name><name><surname>Kogadeeva</surname><given-names>M.</given-names></name><name><surname>Picotti</surname><given-names>P.</given-names></name><name><surname>Meissner</surname><given-names>F.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name><etal/></person-group><article-title>L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity</article-title><source>Cell</source><year>2016</year><volume>167</volume><fpage>829</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.09.031</pub-id><pub-id pub-id-type="pmid">27745970</pub-id></element-citation></ref><ref id="B120-cancers-11-01574"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>C.H.</given-names></name><name><surname>Qiu</surname><given-names>J.</given-names></name><name><surname>O&#x02019;Sullivan</surname><given-names>D.</given-names></name><name><surname>Buck</surname><given-names>M.D.</given-names></name><name><surname>Noguchi</surname><given-names>T.</given-names></name><name><surname>Curtis</surname><given-names>J.D.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Gindin</surname><given-names>M.</given-names></name><name><surname>Gubin</surname><given-names>M.M.</given-names></name><name><surname>van der Windt</surname><given-names>G.J.</given-names></name><etal/></person-group><article-title>Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression</article-title><source>Cell</source><year>2015</year><volume>162</volume><fpage>1229</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.08.016</pub-id><pub-id pub-id-type="pmid">26321679</pub-id></element-citation></ref><ref id="B121-cancers-11-01574"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>P.C.</given-names></name><name><surname>Bihuniak</surname><given-names>J.D.</given-names></name><name><surname>Macintyre</surname><given-names>A.N.</given-names></name><name><surname>Staron</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Amezquita</surname><given-names>R.</given-names></name><name><surname>Tsui</surname><given-names>Y.C.</given-names></name><name><surname>Cui</surname><given-names>G.</given-names></name><name><surname>Micevic</surname><given-names>G.</given-names></name><name><surname>Perales</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses</article-title><source>Cell</source><year>2015</year><volume>162</volume><fpage>1217</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.08.012</pub-id><pub-id pub-id-type="pmid">26321681</pub-id></element-citation></ref><ref id="B122-cancers-11-01574"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Palma</surname><given-names>M.</given-names></name><name><surname>Biziato</surname><given-names>D.</given-names></name><name><surname>Petrova</surname><given-names>T.V.</given-names></name></person-group><article-title>Microenvironmental regulation of tumour angiogenesis</article-title><source>Nat. Rev. Cancer</source><year>2017</year><volume>17</volume><fpage>457</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1038/nrc.2017.51</pub-id><pub-id pub-id-type="pmid">28706266</pub-id></element-citation></ref><ref id="B123-cancers-11-01574"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vegran</surname><given-names>F.</given-names></name><name><surname>Boidot</surname><given-names>R.</given-names></name><name><surname>Michiels</surname><given-names>C.</given-names></name><name><surname>Sonveaux</surname><given-names>P.</given-names></name><name><surname>Feron</surname><given-names>O.</given-names></name></person-group><article-title>Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis</article-title><source>Cancer Res.</source><year>2011</year><volume>71</volume><fpage>2550</fpage><lpage>2560</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2828</pub-id><pub-id pub-id-type="pmid">21300765</pub-id></element-citation></ref><ref id="B124-cancers-11-01574"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonveaux</surname><given-names>P.</given-names></name><name><surname>Copetti</surname><given-names>T.</given-names></name><name><surname>De Saedeleer</surname><given-names>C.J.</given-names></name><name><surname>Vegran</surname><given-names>F.</given-names></name><name><surname>Verrax</surname><given-names>J.</given-names></name><name><surname>Kennedy</surname><given-names>K.M.</given-names></name><name><surname>Moon</surname><given-names>E.J.</given-names></name><name><surname>Dhup</surname><given-names>S.</given-names></name><name><surname>Danhier</surname><given-names>P.</given-names></name><name><surname>Frerart</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e33418</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0033418</pub-id><?supplied-pmid 22428047?><pub-id pub-id-type="pmid">22428047</pub-id></element-citation></ref><ref id="B125-cancers-11-01574"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>D.C.</given-names></name><name><surname>Sohn</surname><given-names>H.A.</given-names></name><name><surname>Park</surname><given-names>Z.Y.</given-names></name><name><surname>Oh</surname><given-names>S.</given-names></name><name><surname>Kang</surname><given-names>Y.K.</given-names></name><name><surname>Lee</surname><given-names>K.M.</given-names></name><name><surname>Kang</surname><given-names>M.</given-names></name><name><surname>Jang</surname><given-names>Y.J.</given-names></name><name><surname>Yang</surname><given-names>S.J.</given-names></name><name><surname>Hong</surname><given-names>Y.K.</given-names></name><etal/></person-group><article-title>A lactate-induced response to hypoxia</article-title><source>Cell</source><year>2015</year><volume>161</volume><fpage>595</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.03.011</pub-id><?supplied-pmid 25892225?><pub-id pub-id-type="pmid">25892225</pub-id></element-citation></ref><ref id="B126-cancers-11-01574"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Bock</surname><given-names>K.</given-names></name><name><surname>Georgiadou</surname><given-names>M.</given-names></name><name><surname>Schoors</surname><given-names>S.</given-names></name><name><surname>Kuchnio</surname><given-names>A.</given-names></name><name><surname>Wong</surname><given-names>B.W.</given-names></name><name><surname>Cantelmo</surname><given-names>A.R.</given-names></name><name><surname>Quaegebeur</surname><given-names>A.</given-names></name><name><surname>Ghesquiere</surname><given-names>B.</given-names></name><name><surname>Cauwenberghs</surname><given-names>S.</given-names></name><name><surname>Eelen</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Role of PFKFB3-driven glycolysis in vessel sprouting</article-title><source>Cell</source><year>2013</year><volume>154</volume><fpage>651</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.06.037</pub-id><?supplied-pmid 23911327?><pub-id pub-id-type="pmid">23911327</pub-id></element-citation></ref><ref id="B127-cancers-11-01574"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoors</surname><given-names>S.</given-names></name><name><surname>De Bock</surname><given-names>K.</given-names></name><name><surname>Cantelmo</surname><given-names>A.R.</given-names></name><name><surname>Georgiadou</surname><given-names>M.</given-names></name><name><surname>Ghesquiere</surname><given-names>B.</given-names></name><name><surname>Cauwenberghs</surname><given-names>S.</given-names></name><name><surname>Kuchnio</surname><given-names>A.</given-names></name><name><surname>Wong</surname><given-names>B.W.</given-names></name><name><surname>Quaegebeur</surname><given-names>A.</given-names></name><name><surname>Goveia</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis</article-title><source>Cell Metab.</source><year>2014</year><volume>19</volume><fpage>37</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.11.008</pub-id><pub-id pub-id-type="pmid">24332967</pub-id></element-citation></ref><ref id="B128-cancers-11-01574"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantelmo</surname><given-names>A.R.</given-names></name><name><surname>Conradi</surname><given-names>L.C.</given-names></name><name><surname>Brajic</surname><given-names>A.</given-names></name><name><surname>Goveia</surname><given-names>J.</given-names></name><name><surname>Kalucka</surname><given-names>J.</given-names></name><name><surname>Pircher</surname><given-names>A.</given-names></name><name><surname>Chaturvedi</surname><given-names>P.</given-names></name><name><surname>Hol</surname><given-names>J.</given-names></name><name><surname>Thienpont</surname><given-names>B.</given-names></name><name><surname>Teuwen</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy</article-title><source>Cancer Cell</source><year>2016</year><volume>30</volume><fpage>968</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.10.006</pub-id><pub-id pub-id-type="pmid">27866851</pub-id></element-citation></ref><ref id="B129-cancers-11-01574"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoors</surname><given-names>S.</given-names></name><name><surname>Bruning</surname><given-names>U.</given-names></name><name><surname>Missiaen</surname><given-names>R.</given-names></name><name><surname>Queiroz</surname><given-names>K.C.</given-names></name><name><surname>Borgers</surname><given-names>G.</given-names></name><name><surname>Elia</surname><given-names>I.</given-names></name><name><surname>Zecchin</surname><given-names>A.</given-names></name><name><surname>Cantelmo</surname><given-names>A.R.</given-names></name><name><surname>Christen</surname><given-names>S.</given-names></name><name><surname>Goveia</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Fatty acid carbon is essential for dNTP synthesis in endothelial cells</article-title><source>Nature</source><year>2015</year><volume>520</volume><fpage>192</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/nature14362</pub-id><pub-id pub-id-type="pmid">25830893</pub-id></element-citation></ref><ref id="B130-cancers-11-01574"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalucka</surname><given-names>J.</given-names></name><name><surname>Bierhansl</surname><given-names>L.</given-names></name><name><surname>Conchinha</surname><given-names>N.V.</given-names></name><name><surname>Missiaen</surname><given-names>R.</given-names></name><name><surname>Elia</surname><given-names>I.</given-names></name><name><surname>Bruning</surname><given-names>U.</given-names></name><name><surname>Scheinok</surname><given-names>S.</given-names></name><name><surname>Treps</surname><given-names>L.</given-names></name><name><surname>Cantelmo</surname><given-names>A.R.</given-names></name><name><surname>Dubois</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Quiescent Endothelial Cells Upregulate Fatty Acid beta-Oxidation for Vasculoprotection via Redox Homeostasis</article-title><source>Cell Metab.</source><year>2018</year><volume>28</volume><fpage>881</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.07.016</pub-id><pub-id pub-id-type="pmid">30146488</pub-id></element-citation></ref><ref id="B131-cancers-11-01574"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lovisa</surname><given-names>S.</given-names></name><name><surname>Kalluri</surname><given-names>R.</given-names></name></person-group><article-title>Fatty Acid Oxidation Regulates the Activation of Endothelial-to-Mesenchymal Transition</article-title><source>Trends Mol. Med.</source><year>2018</year><volume>24</volume><fpage>432</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2018.03.003</pub-id><pub-id pub-id-type="pmid">29573973</pub-id></element-citation></ref><ref id="B132-cancers-11-01574"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>J.</given-names></name><name><surname>Kawagishi</surname><given-names>H.</given-names></name><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wells</surname><given-names>Q.S.</given-names></name><name><surname>Edmunds</surname><given-names>L.R.</given-names></name><name><surname>Fergusson</surname><given-names>M.M.</given-names></name><name><surname>Yu</surname><given-names>Z.X.</given-names></name><name><surname>Rovira</surname><given-names>I.I.</given-names></name><name><surname>Brittain</surname><given-names>E.L.</given-names></name><etal/></person-group><article-title>A Metabolic Basis for Endothelial-to-Mesenchymal Transition</article-title><source>Mol. Cell</source><year>2018</year><volume>69</volume><fpage>689</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.01.010</pub-id><pub-id pub-id-type="pmid">29429925</pub-id></element-citation></ref><ref id="B133-cancers-11-01574"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Vandekeere</surname><given-names>S.</given-names></name><name><surname>Kalucka</surname><given-names>J.</given-names></name><name><surname>Bierhansl</surname><given-names>L.</given-names></name><name><surname>Zecchin</surname><given-names>A.</given-names></name><name><surname>Bruning</surname><given-names>U.</given-names></name><name><surname>Visnagri</surname><given-names>A.</given-names></name><name><surname>Yuldasheva</surname><given-names>N.</given-names></name><name><surname>Goveia</surname><given-names>J.</given-names></name><name><surname>Cruys</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Role of glutamine and interlinked asparagine metabolism in vessel formation</article-title><source>EMBO J.</source><year>2017</year><volume>36</volume><fpage>2334</fpage><lpage>2352</lpage><pub-id pub-id-type="doi">10.15252/embj.201695518</pub-id><pub-id pub-id-type="pmid">28659375</pub-id></element-citation></ref><ref id="B134-cancers-11-01574"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Jang</surname><given-names>C.</given-names></name><name><surname>Arany</surname><given-names>Z.</given-names></name></person-group><article-title>Glutamine fuels proliferation but not migration of endothelial cells</article-title><source>EMBO J.</source><year>2017</year><volume>36</volume><fpage>2321</fpage><lpage>2333</lpage><pub-id pub-id-type="doi">10.15252/embj.201796436</pub-id><?supplied-pmid 28659379?><pub-id pub-id-type="pmid">28659379</pub-id></element-citation></ref><ref id="B135-cancers-11-01574"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmieri</surname><given-names>E.M.</given-names></name><name><surname>Menga</surname><given-names>A.</given-names></name><name><surname>Martin-Perez</surname><given-names>R.</given-names></name><name><surname>Quinto</surname><given-names>A.</given-names></name><name><surname>Riera-Domingo</surname><given-names>C.</given-names></name><name><surname>De Tullio</surname><given-names>G.</given-names></name><name><surname>Hooper</surname><given-names>D.C.</given-names></name><name><surname>Lamers</surname><given-names>W.H.</given-names></name><name><surname>Ghesquiere</surname><given-names>B.</given-names></name><name><surname>McVicar</surname><given-names>D.W.</given-names></name><etal/></person-group><article-title>Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis</article-title><source>Cell Rep.</source><year>2017</year><volume>20</volume><fpage>1654</fpage><lpage>1666</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.07.054</pub-id><?supplied-pmid 28813676?><pub-id pub-id-type="pmid">28813676</pub-id></element-citation></ref><ref id="B136-cancers-11-01574"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eelen</surname><given-names>G.</given-names></name><name><surname>Dubois</surname><given-names>C.</given-names></name><name><surname>Cantelmo</surname><given-names>A.R.</given-names></name><name><surname>Goveia</surname><given-names>J.</given-names></name><name><surname>Bruning</surname><given-names>U.</given-names></name><name><surname>DeRan</surname><given-names>M.</given-names></name><name><surname>Jarugumilli</surname><given-names>G.</given-names></name><name><surname>van Rijssel</surname><given-names>J.</given-names></name><name><surname>Saladino</surname><given-names>G.</given-names></name><name><surname>Comitani</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Role of glutamine synthetase in angiogenesis beyond glutamine synthesis</article-title><source>Nature</source><year>2018</year><volume>561</volume><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0466-7</pub-id><?supplied-pmid 30158707?><pub-id pub-id-type="pmid">30158707</pub-id></element-citation></ref><ref id="B137-cancers-11-01574"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D.</given-names></name><name><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>Hallmarks of Cancer: The Next Generation</article-title><source>Cell</source><year>2011</year><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="B138-cancers-11-01574"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBerardinis</surname><given-names>R.J.</given-names></name><name><surname>Chandel</surname><given-names>N.S.</given-names></name></person-group><article-title>Fundamentals of cancer metabolism</article-title><source>Sci. Adv.</source><year>2016</year><volume>2</volume><fpage>e1600200</fpage><pub-id pub-id-type="doi">10.1126/sciadv.1600200</pub-id><pub-id pub-id-type="pmid">27386546</pub-id></element-citation></ref><ref id="B139-cancers-11-01574"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paudel</surname><given-names>B.B.</given-names></name><name><surname>Quaranta</surname><given-names>V.</given-names></name></person-group><article-title>Metabolic plasticity meets gene regulation</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2019</year><volume>116</volume><fpage>3370</fpage><lpage>3372</lpage><pub-id pub-id-type="doi">10.1073/pnas.1900169116</pub-id><pub-id pub-id-type="pmid">30737291</pub-id></element-citation></ref><ref id="B140-cancers-11-01574"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>D.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><name><surname>Jung</surname><given-names>K.H.</given-names></name><name><surname>Park</surname><given-names>J.H.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Onuchic</surname><given-names>J.N.</given-names></name><name><surname>Kaipparettu</surname><given-names>B.A.</given-names></name><name><surname>Levine</surname><given-names>H.</given-names></name></person-group><article-title>Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2019</year><volume>116</volume><fpage>3909</fpage><lpage>3918</lpage><pub-id pub-id-type="doi">10.1073/pnas.1816391116</pub-id><pub-id pub-id-type="pmid">30733294</pub-id></element-citation></ref><ref id="B141-cancers-11-01574"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perera</surname><given-names>R.M.</given-names></name><name><surname>Bardeesy</surname><given-names>N.</given-names></name></person-group><article-title>Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up</article-title><source>Cancer Discov.</source><year>2015</year><volume>5</volume><fpage>1247</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0671</pub-id><pub-id pub-id-type="pmid">26534901</pub-id></element-citation></ref><ref id="B142-cancers-11-01574"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warburg</surname><given-names>O.</given-names></name><name><surname>Minami</surname><given-names>S.</given-names></name></person-group><article-title>Versuche an &#x000dc;berlebendem Carcinom-gewebe</article-title><source>Klin. Wochenschr.</source><year>1923</year><volume>2</volume><fpage>776</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1007/BF01712130</pub-id></element-citation></ref><ref id="B143-cancers-11-01574"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Butler</surname><given-names>E.B.</given-names></name><name><surname>Tan</surname><given-names>M.</given-names></name></person-group><article-title>Targeting cellular metabolism to improve cancer therapeutics</article-title><source>Cell Death Dis.</source><year>2013</year><volume>4</volume><fpage>e532</fpage><pub-id pub-id-type="doi">10.1038/cddis.2013.60</pub-id><pub-id pub-id-type="pmid">23470539</pub-id></element-citation></ref><ref id="B144-cancers-11-01574"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birsoy</surname><given-names>K.</given-names></name><name><surname>Sabatini</surname><given-names>D.M.</given-names></name><name><surname>Possemato</surname><given-names>R.</given-names></name></person-group><article-title>Untuning the tumor metabolic machine: Targeting cancer metabolism: A bedside lesson</article-title><source>Nat. Med.</source><year>2012</year><volume>18</volume><fpage>1022</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1038/nm.2870</pub-id><?supplied-pmid 22772555?><pub-id pub-id-type="pmid">22772555</pub-id></element-citation></ref><ref id="B145-cancers-11-01574"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tennant</surname><given-names>D.A.</given-names></name><name><surname>Dur&#x000e1;n</surname><given-names>R.V.</given-names></name><name><surname>Gottlieb</surname><given-names>E.</given-names></name></person-group><article-title>Targeting metabolic transformation for cancer therapy</article-title><source>Nat. Rev. Cancer</source><year>2010</year><volume>10</volume><fpage>267</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1038/nrc2817</pub-id><?supplied-pmid 20300106?><pub-id pub-id-type="pmid">20300106</pub-id></element-citation></ref><ref id="B146-cancers-11-01574"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Heiden</surname><given-names>M.G.</given-names></name></person-group><article-title>Targeting cancer metabolism: A therapeutic window opens</article-title><source>Nat. Rev. Drug Discov.</source><year>2011</year><volume>10</volume><fpage>671</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1038/nrd3504</pub-id><?supplied-pmid 21878982?><pub-id pub-id-type="pmid">21878982</pub-id></element-citation></ref><ref id="B147-cancers-11-01574"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamanaka</surname><given-names>R.B.</given-names></name><name><surname>Chandel</surname><given-names>N.S.</given-names></name></person-group><article-title>Targeting glucose metabolism for cancer therapy</article-title><source>J. Exp. Med.</source><year>2012</year><volume>209</volume><fpage>211</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1084/jem.20120162</pub-id><?supplied-pmid 22330683?><pub-id pub-id-type="pmid">22330683</pub-id></element-citation></ref><ref id="B148-cancers-11-01574"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Bergmeier</surname><given-names>S.</given-names></name><name><surname>Qian</surname><given-names>Y.</given-names></name><name><surname>Akbar</surname><given-names>H.</given-names></name><name><surname>Colvin</surname><given-names>R.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Tong</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo</article-title><source>Mol. Cancer Ther.</source><year>2012</year><volume>11</volume><fpage>1672</fpage><lpage>1682</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-0131</pub-id><?supplied-pmid 22689530?><pub-id pub-id-type="pmid">22689530</pub-id></element-citation></ref><ref id="B149-cancers-11-01574"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Mjiyad</surname><given-names>N.</given-names></name><name><surname>Caro-Maldonado</surname><given-names>A.</given-names></name><name><surname>Ram&#x000ed;rez-Peinado</surname><given-names>S.</given-names></name><name><surname>Mu&#x000f1;oz-Pinedo</surname><given-names>C.</given-names></name></person-group><article-title>Sugar-free approaches to cancer cell killing</article-title><source>Oncogene</source><year>2010</year><volume>30</volume><fpage>253</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.466</pub-id><pub-id pub-id-type="pmid">20972457</pub-id></element-citation></ref><ref id="B150-cancers-11-01574"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Xue</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Xiao</surname><given-names>W.</given-names></name><name><surname>Mo</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name></person-group><article-title>Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model</article-title><source>J. Cancer Res. Clin. Oncol.</source><year>2011</year><volume>137</volume><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/s00432-010-0860-5</pub-id><pub-id pub-id-type="pmid">20336315</pub-id></element-citation></ref><ref id="B151-cancers-11-01574"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>A.</given-names></name><name><surname>Cooper</surname><given-names>C.R.</given-names></name><name><surname>Gouw</surname><given-names>A.M.</given-names></name><name><surname>Dinavahi</surname><given-names>R.</given-names></name><name><surname>Maitra</surname><given-names>A.</given-names></name><name><surname>Deck</surname><given-names>L.M.</given-names></name><name><surname>Royer</surname><given-names>R.E.</given-names></name><name><surname>Vander Jagt</surname><given-names>D.L.</given-names></name><name><surname>Semenza</surname><given-names>G.L.</given-names></name><name><surname>Dang</surname><given-names>C.V.</given-names></name></person-group><article-title>Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>2037</fpage><lpage>2042</lpage><pub-id pub-id-type="doi">10.1073/pnas.0914433107</pub-id><pub-id pub-id-type="pmid">20133848</pub-id></element-citation></ref><ref id="B152-cancers-11-01574"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnet</surname><given-names>S.</given-names></name><name><surname>Archer</surname><given-names>S.L.</given-names></name><name><surname>Allalunis-Turner</surname><given-names>J.</given-names></name><name><surname>Haromy</surname><given-names>A.</given-names></name><name><surname>Beaulieu</surname><given-names>C.</given-names></name><name><surname>Thompson</surname><given-names>R.</given-names></name><name><surname>Lee</surname><given-names>C.T.</given-names></name><name><surname>Lopaschuk</surname><given-names>G.D.</given-names></name><name><surname>Puttagunta</surname><given-names>L.</given-names></name><name><surname>Bonnet</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A Mitochondria-K+ Channel Axis Is Suppressed in Cancer and Its Normalization Promotes Apoptosis and Inhibits Cancer Growth</article-title><source>Cancer Cell</source><year>2007</year><volume>11</volume><fpage>37</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.10.020</pub-id><pub-id pub-id-type="pmid">17222789</pub-id></element-citation></ref><ref id="B153-cancers-11-01574"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michelakis</surname><given-names>E.D.</given-names></name><name><surname>Webster</surname><given-names>L.</given-names></name><name><surname>Mackey</surname><given-names>J.R.</given-names></name></person-group><article-title>Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer</article-title><source>Br. J. Cancer</source><year>2008</year><volume>99</volume><fpage>989</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604554</pub-id><pub-id pub-id-type="pmid">18766181</pub-id></element-citation></ref><ref id="B154-cancers-11-01574"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flavin</surname><given-names>R.</given-names></name><name><surname>Peluso</surname><given-names>S.</given-names></name><name><surname>Nguyen</surname><given-names>P.L.</given-names></name><name><surname>Loda</surname><given-names>M.</given-names></name></person-group><article-title>Fatty acid synthase as a potential therapeutic target in cancer</article-title><source>Future Oncol. (Lond. Engl.)</source><year>2010</year><volume>6</volume><fpage>551</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.2217/fon.10.11</pub-id><?supplied-pmid 20373869?><pub-id pub-id-type="pmid">20373869</pub-id></element-citation></ref><ref id="B155-cancers-11-01574"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thupari</surname><given-names>J.N.</given-names></name><name><surname>Pinn</surname><given-names>M.L.</given-names></name><name><surname>Kuhajda</surname><given-names>F.P.</given-names></name></person-group><article-title>Fatty Acid Synthase Inhibition in Human Breast Cancer Cells Leads to Malonyl-CoA-Induced Inhibition of Fatty Acid Oxidation and Cytotoxicity</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2001</year><volume>285</volume><fpage>217</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2001.5146</pub-id><?supplied-pmid 11444828?><pub-id pub-id-type="pmid">11444828</pub-id></element-citation></ref><ref id="B156-cancers-11-01574"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angeles</surname><given-names>T.S.</given-names></name><name><surname>Hudkins</surname><given-names>R.L.</given-names></name></person-group><article-title>Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors</article-title><source>Expert Opin. Drug Discov.</source><year>2016</year><volume>11</volume><fpage>1187</fpage><lpage>1199</lpage><pub-id pub-id-type="doi">10.1080/17460441.2016.1245286</pub-id><?supplied-pmid 27701891?><pub-id pub-id-type="pmid">27701891</pub-id></element-citation></ref><ref id="B157-cancers-11-01574"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.-S.</given-names></name><name><surname>Lei</surname><given-names>J.-P.</given-names></name><name><surname>Wei</surname><given-names>G.-Q.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>C.-Y.</given-names></name><name><surname>Jiang</surname><given-names>H.-Z.</given-names></name></person-group><article-title>Natural fatty acid synthase inhibitors as potent therapeutic agents for cancers: A review</article-title><source>Pharm. Biol.</source><year>2016</year><volume>54</volume><fpage>1919</fpage><lpage>1925</lpage><pub-id pub-id-type="doi">10.3109/13880209.2015.1113995</pub-id><?supplied-pmid 26864638?><pub-id pub-id-type="pmid">26864638</pub-id></element-citation></ref><ref id="B158-cancers-11-01574"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L.</given-names></name><name><surname>Alesi</surname><given-names>G.N.</given-names></name><name><surname>Kang</surname><given-names>S.</given-names></name></person-group><article-title>Glutaminolysis as a target for cancer therapy</article-title><source>Oncogene</source><year>2015</year><volume>35</volume><fpage>3619</fpage><lpage>3625</lpage><pub-id pub-id-type="doi">10.1038/onc.2015.447</pub-id><?supplied-pmid 26592449?><pub-id pub-id-type="pmid">26592449</pub-id></element-citation></ref><ref id="B159-cancers-11-01574"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Meng</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Bian</surname><given-names>J.</given-names></name></person-group><article-title>Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions</article-title><source>J. Med. Chem.</source><year>2019</year><volume>62</volume><fpage>1096</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00961</pub-id><pub-id pub-id-type="pmid">30148361</pub-id></element-citation></ref><ref id="B160-cancers-11-01574"><label>160.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S. National Library of Medicine</collab></person-group><article-title>NCT03894540. ClinicalTrials.gov</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03894540?term=NCT03894540&#x00026;rank=1">https://clinicaltrials.gov/ct2/show/NCT03894540?term=NCT03894540&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-08-27">(accessed on 27 August 2019)</date-in-citation></element-citation></ref><ref id="B161-cancers-11-01574"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabnis</surname><given-names>H.S.</given-names></name><name><surname>Somasagara</surname><given-names>R.R.</given-names></name><name><surname>Bunting</surname><given-names>K.D.</given-names></name></person-group><article-title>Targeting MYC Dependence by Metabolic Inhibitors in Cancer</article-title><source>Genes</source><year>2017</year><volume>8</volume><elocation-id>114</elocation-id><pub-id pub-id-type="doi">10.3390/genes8040114</pub-id></element-citation></ref><ref id="B162-cancers-11-01574"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalaany</surname><given-names>N.Y.</given-names></name><name><surname>Sabatini</surname><given-names>D.M.</given-names></name></person-group><article-title>Tumours with PI3K activation are resistant to dietary restriction</article-title><source>Nature</source><year>2009</year><volume>458</volume><fpage>725</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1038/nature07782</pub-id><pub-id pub-id-type="pmid">19279572</pub-id></element-citation></ref><ref id="B163-cancers-11-01574"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Tao</surname><given-names>Y.</given-names></name><name><surname>Duran</surname><given-names>A.</given-names></name><name><surname>Llado</surname><given-names>V.</given-names></name><name><surname>Galvez</surname><given-names>A.</given-names></name><name><surname>Barger</surname><given-names>J.F.</given-names></name><name><surname>Castilla</surname><given-names>E.A.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Yajima</surname><given-names>T.</given-names></name><name><surname>Porollo</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Control of nutrient stress-induced metabolic reprogramming by PKC&#x003b6; in tumorigenesis</article-title><source>Cell</source><year>2013</year><volume>152</volume><fpage>599</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.12.028</pub-id><pub-id pub-id-type="pmid">23374352</pub-id></element-citation></ref><ref id="B164-cancers-11-01574"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>O.C.</given-names></name><name><surname>Choudhury</surname><given-names>S.</given-names></name><name><surname>Kolukula</surname><given-names>V.</given-names></name><name><surname>Vietsch</surname><given-names>E.E.</given-names></name><name><surname>Catania</surname><given-names>J.</given-names></name><name><surname>Preet</surname><given-names>A.</given-names></name><name><surname>Reynoso</surname><given-names>K.</given-names></name><name><surname>Bargonetti</surname><given-names>J.</given-names></name><name><surname>Wellstein</surname><given-names>A.</given-names></name><name><surname>Albanese</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Dietary downregulation of mutant p53 levels via glucose restriction: Mechanisms and implications for tumor therapy</article-title><source>Cell Cycle (Georget. Tex.)</source><year>2012</year><volume>11</volume><fpage>4436</fpage><lpage>4446</lpage><pub-id pub-id-type="doi">10.4161/cc.22778</pub-id></element-citation></ref><ref id="B165-cancers-11-01574"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker-Samuel</surname><given-names>S.</given-names></name><name><surname>Ramasawmy</surname><given-names>R.</given-names></name><name><surname>Torrealdea</surname><given-names>F.</given-names></name><name><surname>Rega</surname><given-names>M.</given-names></name><name><surname>Rajkumar</surname><given-names>V.</given-names></name><name><surname>Johnson</surname><given-names>S.P.</given-names></name><name><surname>Richardson</surname><given-names>S.</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>M.</given-names></name><name><surname>Parkes</surname><given-names>H.G.</given-names></name><name><surname>Arstad</surname><given-names>E.</given-names></name><etal/></person-group><article-title>In vivo imaging of glucose uptake and metabolism in tumors</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>1067</fpage><lpage>1072</lpage><pub-id pub-id-type="doi">10.1038/nm.3252</pub-id><?supplied-pmid 23832090?><pub-id pub-id-type="pmid">23832090</pub-id></element-citation></ref><ref id="B166-cancers-11-01574"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Park</surname><given-names>I.</given-names></name><name><surname>Nelson</surname><given-names>S.J.</given-names></name></person-group><article-title>Imaging tumor metabolism using in vivo magnetic resonance spectroscopy</article-title><source>Cancer J. (Sudbury Mass.)</source><year>2015</year><volume>21</volume><fpage>123</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1097/PPO.0000000000000097</pub-id><?supplied-pmid 25815853?><pub-id pub-id-type="pmid">25815853</pub-id></element-citation></ref><ref id="B167-cancers-11-01574"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeersch</surname><given-names>K.A.</given-names></name><name><surname>Styczynski</surname><given-names>M.P.</given-names></name></person-group><article-title>Applications of metabolomics in cancer research</article-title><source>J. Carcinog.</source><year>2013</year><volume>12</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.4103/1477-3163.113622</pub-id><?supplied-pmid 23858297?><pub-id pub-id-type="pmid">23858297</pub-id></element-citation></ref><ref id="B168-cancers-11-01574"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabnis</surname><given-names>H.</given-names></name><name><surname>Bradley</surname><given-names>H.L.</given-names></name><name><surname>Bunting</surname><given-names>S.T.</given-names></name><name><surname>Cooper</surname><given-names>T.M.</given-names></name><name><surname>Bunting</surname><given-names>K.D.</given-names></name></person-group><article-title>Capillary nano-immunoassay for Akt 1/2/3 and 4EBP1 phosphorylation in acute myeloid leukemia</article-title><source>J. Transl. Med.</source><year>2014</year><volume>12</volume><fpage>166</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-12-166</pub-id><?supplied-pmid 24923301?><pub-id pub-id-type="pmid">24923301</pub-id></element-citation></ref><ref id="B169-cancers-11-01574"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>W.</given-names></name><name><surname>Chang</surname><given-names>C.-P.B.</given-names></name><name><surname>Tsao</surname><given-names>C.-C.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name></person-group><article-title>Oligomycin-induced bioenergetic adaptation in cancer cells with heterogeneous bioenergetic organization</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>12647</fpage><lpage>12654</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.084194</pub-id><?supplied-pmid 20110356?><pub-id pub-id-type="pmid">20110356</pub-id></element-citation></ref><ref id="B170-cancers-11-01574"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elgendy</surname><given-names>M.</given-names></name><name><surname>Ciro</surname><given-names>M.</given-names></name><name><surname>Hosseini</surname><given-names>A.</given-names></name><name><surname>Weiszmann</surname><given-names>J.</given-names></name><name><surname>Mazzarella</surname><given-names>L.</given-names></name><name><surname>Ferrari</surname><given-names>E.</given-names></name><name><surname>Cazzoli</surname><given-names>R.</given-names></name><name><surname>Curigliano</surname><given-names>G.</given-names></name><name><surname>DeCensi</surname><given-names>A.</given-names></name><name><surname>Bonanni</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3beta-MCL-1 Axis</article-title><source>Cancer Cell</source><year>2019</year><volume>35</volume><fpage>798</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.03.007</pub-id><pub-id pub-id-type="pmid">31031016</pub-id></element-citation></ref><ref id="B171-cancers-11-01574"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haq</surname><given-names>R.</given-names></name><name><surname>Shoag</surname><given-names>J.</given-names></name><name><surname>Andreu-Perez</surname><given-names>P.</given-names></name><name><surname>Yokoyama</surname><given-names>S.</given-names></name><name><surname>Edelman</surname><given-names>H.</given-names></name><name><surname>Rowe</surname><given-names>G.C.</given-names></name><name><surname>Frederick</surname><given-names>D.T.</given-names></name><name><surname>Hurley</surname><given-names>A.D.</given-names></name><name><surname>Nellore</surname><given-names>A.</given-names></name><name><surname>Kung</surname><given-names>A.L.</given-names></name><etal/></person-group><article-title>Oncogenic BRAF regulates oxidative metabolism via PGC1&#x003b1; and MITF</article-title><source>Cancer Cell</source><year>2013</year><volume>23</volume><fpage>302</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.02.003</pub-id><pub-id pub-id-type="pmid">23477830</pub-id></element-citation></ref><ref id="B172-cancers-11-01574"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parmenter</surname><given-names>T.J.</given-names></name><name><surname>Kleinschmidt</surname><given-names>M.</given-names></name><name><surname>Kinross</surname><given-names>K.M.</given-names></name><name><surname>Bond</surname><given-names>S.T.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Kaadige</surname><given-names>M.R.</given-names></name><name><surname>Rao</surname><given-names>A.</given-names></name><name><surname>Sheppard</surname><given-names>K.E.</given-names></name><name><surname>Hugo</surname><given-names>W.</given-names></name><name><surname>Pupo</surname><given-names>G.M.</given-names></name><etal/></person-group><article-title>Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis</article-title><source>Cancer Discov.</source><year>2014</year><volume>4</volume><fpage>423</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0440</pub-id><pub-id pub-id-type="pmid">24469106</pub-id></element-citation></ref><ref id="B173-cancers-11-01574"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muir</surname><given-names>A.</given-names></name><name><surname>Danai</surname><given-names>L.V.</given-names></name><name><surname>Vander Heiden</surname><given-names>M.G.</given-names></name></person-group><article-title>Microenvironmental regulation of cancer cell metabolism: Implications for experimental design and translational studies</article-title><source>Dis. Models Mech.</source><year>2018</year><volume>11</volume><fpage>dmm035758</fpage><pub-id pub-id-type="doi">10.1242/dmm.035758</pub-id></element-citation></ref><ref id="B174-cancers-11-01574"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S.</given-names></name><name><surname>Sharife</surname><given-names>H.</given-names></name><name><surname>Kreisel</surname><given-names>T.</given-names></name><name><surname>Mogilevsky</surname><given-names>M.</given-names></name><name><surname>Bar-Lev</surname><given-names>L.</given-names></name><name><surname>Grunewald</surname><given-names>M.</given-names></name><name><surname>Aizenshtein</surname><given-names>E.</given-names></name><name><surname>Karni</surname><given-names>R.</given-names></name><name><surname>Paldor</surname><given-names>I.</given-names></name><name><surname>Shlomi</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Intra-Tumoral Metabolic Zonation and Resultant Phenotypic Diversification Are Dictated by Blood Vessel Proximity</article-title><source>Cell metab.</source><year>2019</year><volume>30</volume><fpage>201</fpage><lpage>211 e206</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2019.04.003</pub-id><pub-id pub-id-type="pmid">31056286</pub-id></element-citation></ref><ref id="B175-cancers-11-01574"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson-Tessi</surname><given-names>M.</given-names></name><name><surname>Gillies</surname><given-names>R.J.</given-names></name><name><surname>Gatenby</surname><given-names>R.A.</given-names></name><name><surname>Anderson</surname><given-names>A.R.</given-names></name></person-group><article-title>Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes</article-title><source>Cancer res.</source><year>2015</year><volume>75</volume><fpage>1567</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-1428</pub-id><?supplied-pmid 25878146?><pub-id pub-id-type="pmid">25878146</pub-id></element-citation></ref><ref id="B176-cancers-11-01574"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estrella</surname><given-names>V.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Lloyd</surname><given-names>M.</given-names></name><name><surname>Wojtkowiak</surname><given-names>J.</given-names></name><name><surname>Cornnell</surname><given-names>H.H.</given-names></name><name><surname>Ibrahim-Hashim</surname><given-names>A.</given-names></name><name><surname>Bailey</surname><given-names>K.</given-names></name><name><surname>Balagurunathan</surname><given-names>Y.</given-names></name><name><surname>Rothberg</surname><given-names>J.M.</given-names></name><name><surname>Sloane</surname><given-names>B.F.</given-names></name><etal/></person-group><article-title>Acidity generated by the tumor microenvironment drives local invasion</article-title><source>Cancer Res.</source><year>2013</year><volume>73</volume><fpage>1524</fpage><lpage>1535</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-2796</pub-id><?supplied-pmid 23288510?><pub-id pub-id-type="pmid">23288510</pub-id></element-citation></ref><ref id="B177-cancers-11-01574"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smallbone</surname><given-names>K.</given-names></name><name><surname>Gatenby</surname><given-names>R.A.</given-names></name><name><surname>Gillies</surname><given-names>R.J.</given-names></name><name><surname>Maini</surname><given-names>P.K.</given-names></name><name><surname>Gavaghan</surname><given-names>D.J.</given-names></name></person-group><article-title>Metabolic changes during carcinogenesis: Potential impact on invasiveness</article-title><source>J. Theor. Biol.</source><year>2007</year><volume>244</volume><fpage>703</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2006.09.010</pub-id><?supplied-pmid 17055536?><pub-id pub-id-type="pmid">17055536</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="cancers-11-01574-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Reproduction of original drawings representing the microscopic appearance of cancer cells isolated from different human neoplasia, as reported in Muller&#x02019;s 1838 work on cancer [<xref rid="B1-cancers-11-01574" ref-type="bibr">1</xref>]. Panel 2 and panel 17 depict mono- and poly-nucleated tumor cells in a &#x0201c;reticular&#x0201d; carcinoma, and heterogeneous spindle-shaped cells isolated from a lower jaw osteocarcinoma respectively (Table II, page 69); panel 4 represents different polynucleated cells isolated from a tumor of the parotid gland (Table III, page 71); panel 18 shows different morphological cells comprehending pigmented cells (<bold>e</bold>) isolated from an osteocarcinoma (Table I, page 67).</p></caption><graphic xlink:href="cancers-11-01574-g001"/></fig><fig id="cancers-11-01574-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Current models of tumor evolution. According to the branching model (left), tumor complexity increases over time due to continuous accumulation of genomic events; in a punctuate evolution model (right), the full tumor complexity is acquired early during progression due to cataclysmic genomic events.</p></caption><graphic xlink:href="cancers-11-01574-g002"/></fig><fig id="cancers-11-01574-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Tumors are complex ecosystems that constantly evolve over time in response to intrinsic and extrinsic perturbation. The principal components of tumor heterogeneity are deeply interconnected with each other and can influence and be influenced by tumor metabolism.</p></caption><graphic xlink:href="cancers-11-01574-g003"/></fig><fig id="cancers-11-01574-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Effects of prototypical oncogenes and tumor suppressor genes on major metabolic processes. (PPP, pentose phosphate pathway; TCA, tricarboxylic acid cycle; OAA, oxaloacetate; &#x003b1;-KG, alpha-ketoglutarate).</p></caption><graphic xlink:href="cancers-11-01574-g004"/></fig></floats-group></article>